Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights

– UDENYCA® autoinjector approved and ready for May 2023 launch –

– CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation –

– FDA inspection of toripalimab manufacturing site scheduled for May 2023 –

– Toripalimab launch anticipated in Q3 2023, if approved –

– YUSIMRY™ ready for planned July 2023 launch –

– FDA review of UDENYCA® OBI BLA supplement progressing; launch anticipated in 2023, if approved –

– Net product revenue of $32.4 million in the first quarter 2023 –

– Conference call today at 5:00 p.m. Eastern Time –

REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, “the Company”, Nasdaq: CHRS), today reported financial results for the quarter ended March 31, 2023 and recent business highlights:

RECENT BUSINESS HIGHLIGHTS

CIMERLI®

  • On April 1st, the permanent, product-specific Q-code assigned to CIMERLI® (ranibizumab-eqrn) by the U.S. Centers for Medicare & Medicaid Services (CMS) became active, enabling more efficient, electronic billing processes and reducing time to reimbursement for providers. Demand increased sharply as expected in April, with over 7,000 units of CIMERLI® shipped, exceeding in one month 70% of Q1 unit sales.

UDENYCA®

  • The FDA approved a single-dose, prefilled autoinjector (AI) presentation of UDENYCA® (pegfilgrastim-cbqv) on March 3, 2023, which represents the first presentation innovation in the pegfilgrastim space in eight years and highlights Coherus’ commitment to developing innovative treatments that expand access and address the needs of patients undergoing cancer treatment. Coherus plans to launch UDENYCA® AI later this month.
  • The FDA review of the prior approval supplement for Coherus’ third pegfilgrastim presentation, the UDENYCA® on-body injector (OBI), is ongoing, and Coherus plans to launch UDENYCA® OBI directly upon potential approval later this year.

Toripalimab

  • The U.S. Food and Drug Administration (FDA) has notified the Company that it plans to conduct the required inspection of the toripalimab manufacturing facility in China later in May 2023. The inspections, previously hindered by COVID-related travel restrictions, are part of the FDA’s review of the biologics license application (BLA) for toripalimab, a PD-1 inhibitor for the treatment of nasopharyngeal carcinoma (NPC). Coherus anticipates potential FDA approval and commercial launch of toripalimab in the U.S. in Q3 2023.
  • Positive toripalimab clinical data will be presented at the upcoming 2023 ASCO Annual Meeting including the final overall survival analysis for JUPITER-02 in NPC, updated overall survival analysis for CHOICE-01 in advanced non-small cell lung cancer (NSCLC), interim analysis of event-free survival for NEOTORCH in Stage II/III NSCLC, and clinical data for TORCHLIGHT in advanced triple-negative breast cancer.

YUSIMRY™

  • Preparations are underway for commercial launch in Q3 2023 of YUSIMRY™, a Humira biosimilar with a citrate-free and sting-free formulation delivered via a state-of-the-art autoinjector. Coherus has invested in robust, large-scale manufacturing capabilities to ensure ample supply upon launch.
  • The FDA recently approved YUSIMRY prior approval supplements for the autoinjector presentation and for large-scale drug supply manufacturing.

Novel Immuno-oncology Pipeline

  • Patient recruitment is underway in the U.S.-based Phase 1/2 clinical trial of CHS-006, a TIGIT-targeted antibody in combination with toripalimab in patients with advanced solid tumors (NCT05757492).
  • Coherus expects to file an IND by year end for CHS-1000, a novel ILT4-targeted antibody.

“With the approval of the UDENYCA® autoinjector, the activation of the CMS-assigned Q-code and the other product launches planned across our diversified portfolio, we are well positioned for accelerated revenue growth for the remainder of 2023 and beyond. We continue to sharply focus on commercial execution, and are already beginning to see the impact of the Q-code on CIMERLI® sales at the start of the second quarter,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “Innovative presentations offering differentiated value, such as the UDENYCA® autoinjector launching this month, as well as the UDENYCA® on-body injector presentation, with anticipated approval and launch later in the year, will offer patients and physicians unprecedented choice in their treatment options, driving market share gains and long-term value for the franchise.”

Mr. Lanfear continued, “Inspections of the toripalimab manufacturing facilities are scheduled for later this month, with clinical site inspections to follow. NPC patients currently have no FDA approved therapies, and toripalimab has the potential to be the new standard of care for across multiple lines of treatment, if approved. We are planning for approval and launch in the third quarter.”

FIRST QUARTER 2023 FINANCIAL RESULTS

Net revenue was $32.4 million during the three months ended March 31, 2023 and included $26.2 million of net sales of UDENYCA and $6.2 million of net sales of CIMERLI®, which was launched in October 2022. Net sales of UDENYCA® for the first quarter of 2023 were reduced by a $1.7 million charge for a contingent liability related to resolving a dispute regarding certain sales from October 2020 through December 2021. Net revenue was $60.1 million during the three months ended March 31, 2022. The decline was primarily due to a decrease in the number of units of UDENYCA® sold as well as a lower net realized price due to increased competition.

Cost of goods sold (COGS) was $16.9 million and $9.4 million during the three months ended March 31, 2023 and 2022, respectively. UDENYCA® COGS includes a mid-single digit royalty on net sales payable through the first half of 2024, and CIMERLI® COGS includes a low to mid 50% royalty on gross profits. COGS for the first quarter of 2023 also includes $3.0 million in contract modification fees with one of our manufacturers and $2.7 million in write-offs of inventory that was damaged during processing at one of our manufacturers.

Research and development (R&D) expense for the three months ended March 31, 2023 was $34.2 million. R&D expense for the three months ended March 31, 2022 was $82.9 million, which included a $35 million option exercise fee paid to Junshi Biosciences to license CHS-006, a clinical-stage TIGIT-targeted antibody, as well as development and manufacturing costs for clinical and preclinical pipeline programs.

Selling, general and administrative (SG&A) expense for the three months ended March 31, 2023 was $49.2 million compared to $48.8 million for the same period in 2022. The increase was primarily due to $1.3 million in restructuring charges from our reduction in force that occurred in the first quarter of 2023.

Net loss for the first quarter of 2023 was $75.7 million, or $(0.96) per share on a diluted basis, compared to a net loss of $96.1 million, or $(1.24) per share on a diluted basis for the same period in 2022.

Non-GAAP net loss for the first quarter of 2023 was $59.5 million, or $(0.75) per share on a diluted basis, compared to non-GAAP net loss of $77.0 million, or $(1.00) per share on a diluted basis for the same period in 2022. See “Non-GAAP Financial Measures” below for a discussion on how Coherus calculates non-GAAP net loss and a reconciliation to the most directly comparable GAAP measures.

Cash, cash equivalents and investments in marketable securities were $128.1 million as of March 31, 2023, compared to $191.7 million at December 31, 2022.

2023 Revenue and R&D and SG&A Expense Guidance

Coherus expects its 2023 net product revenue will exceed $275 million, including at least $100 million of CIMERLI® net revenue.

Coherus projects combined R&D and SG&A expenses for 2023 to be in the range of $315 to $335 million. This guidance includes approximately $50 million of stock-based compensation expense and excludes any potential collaboration upfront payments to Klinge Pharma for the in-license of its Eylea® biosimilar program or milestones payments to Junshi Biosciences due upon U.S. approval of toripalimab.

This financial guidance also excludes the effects of any potential future strategic acquisitions, collaborations or investments, the exercise of rights or options related to collaboration programs, and any other transactions or circumstances not yet identified or quantified. This guidance is subject to a number of risks and uncertainties. See Forward-Looking Statements described in the section below.

Conference Call Information

When: Monday, May 8th, 2023, starting at 5:00 p.m. Eastern Time

To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI12e6d284dae8440e91891f2cef4f2097

Please dial-in 15 minutes early to ensure a timely connection to the call.

Webcast Link: https://edge.media-server.com/mmc/p/ugoyrevj
A replay of the webcast will be archived on the “Investors” section of the Coherus website at http://investors.coherus.com.

About Coherus BioSciences

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The BLA for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic NPC is currently under review by the FDA.

Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, and CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, in the U.S., and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the U.S. in 2023.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ ability to build its immuno-oncology franchise to achieve a leading market position; Coherus’ ability to generate cash and net sales; Coherus’ investment plans; Coherus’ future projections for R&D expense, SG&A expense, net product revenue and CIMERLI® revenue; Coherus’ expectations about filing an IND for its ILT4 molecule; Coherus’ expectations about gaining approval and launching its product candidates; and Coherus’ expectations about any increased sales of CIMERLI® in future periods.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of Coherus’ competitive position; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus’ business, the need to finish inspections in China and the timing of Coherus’ regulatory filings; the risk of FDA review issues; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ products and product candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 filed with the Securities and Exchange Commission on May 8, 2023, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission. Coherus’ results for the quarter ended March 31, 2023 are not necessarily indicative of our operating results for any future periods.

UDENYCA®, CIMERLI® and YUSIMRY™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.
UDENYCA® and CIMERLI® are registered trademarks and YUSIMRY™ is a trademark of Coherus BioSciences, Inc.

Neulasta® is a registered trademark of Amgen, Inc.
Lucentis® is a registered trademark of Genentech, Inc.
Humira® is a registered trademark of AbbVie Inc.

Coherus Contact Information:

For Investors:
Marek Ciszewski, J.D.
SVP Investor Relations
Coherus BioSciences, Inc.
[email protected]

For Media:
Jodi Sievers
VP, Corporate Communications
Coherus BioSciences, Inc.
[email protected]

 
Coherus BioSciences, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(unaudited)
             
    Three Months Ended
    March 31, 
    2023
  2022
Net revenue   $ 32,436     $ 60,115  
Costs and expenses:            
Cost of goods sold     16,874       9,370  
Research and development     34,154       82,917  
Selling, general and administrative     49,153       48,753  
Total costs and expenses     100,181       141,040  
Loss from operations     (67,745 )     (80,925 )
Interest expense     (9,712 )     (8,969 )
Loss on debt extinguishment           (6,222 )
Other income (expense), net     1,728       32  
Loss before income taxes     (75,729 )     (96,084 )
Income tax provision            
Net loss   $ (75,729 )   $ (96,084 )
             
Basic and diluted net loss per share   $ (0.96 )   $ (1.24 )
             
Weighted-average number of shares used in computing basic and diluted net loss per share     79,268,853       77,253,699  
                 

Coherus BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
             
    March 31,    December 31, 
    2023
  2022
Assets            
Cash and cash equivalents   $ 16,145     $ 63,547  
Investments in marketable securities     111,944       128,134  
Trade receivables, net     101,458       109,964  
Inventory     114,487       115,051  
Other assets     58,392       64,151  
Total assets   $ 402,426     $ 480,847  
             
Liabilities and Stockholders’ Deficit            
Accrued rebates, fees and reserve   $ 55,697     $ 54,461  
Term loans     245,718       245,483  
Convertible notes     225,900       225,575  
Other liabilities     71,618       92,746  
Total stockholders’ deficit     (196,507 )     (137,418 )
Total liabilities and stockholders’ deficit   $ 402,426     $ 480,847  
                 

Coherus BioSciences, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
             
    Three Months Ended
    March 31, 
    2023
  2022
Cash, cash equivalents and restricted cash at beginning of the period   $ 63,987     $ 417,635  
             
Net cash used in operating activities     (68,732 )     (54,045 )
             
Proceeds from maturities of investments in marketable securities     17,500        
Option payment to Junshi Biosciences           (35,000 )
Other investing activities, net     26       (615 )
Net cash provided by (used in) investing activities     17,526       (35,615 )
             
Proceeds from 2027 Term Loans, net of debt discount & issuance costs           191,190  
Proceeds from issuance of common stock upon exercise of stock options     103       544  
Proceeds from issuance of common stock under ATM Offering, net of issuance costs     6,835        
Taxes paid related to net share settlement of RSUs     (2,781 )     (2,658 )
Repayment of 2022 Convertible Notes and premiums           (109,000 )
Repayment of 2025 Term Loan, premiums and exit fees           (81,750 )
Other financing activities     (353 )     (181 )
Net cash provided by (used in) financing activities     3,804       (1,855 )
             
Net decrease in cash, cash equivalents and restricted cash     (47,402 )     (91,515 )
             
Cash, cash equivalents and restricted cash at end of the period   $ 16,585     $ 326,120  
             
Reconciliation of cash, cash equivalents, and restricted cash            
Cash and cash equivalents   $ 16,145     $ 325,680  
Restricted cash balance     440       440  
Cash, cash equivalents and restricted cash   $ 16,585     $ 326,120  
                 

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net loss, and the related per share measures, which exclude from net loss, and the related per share measures, stock-based compensation expense, loss on debt extinguishment and restructuring charges related to our reduction in workforce. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.

Coherus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

 
Coherus BioSciences, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss
(in thousands, except share and per share data)
(unaudited)
             
    Three Months Ended
    March 31, 
    2023
  2022
GAAP net loss   $ (75,729 )   $ (96,084 )
Adjustments:            
Stock-based compensation expense(1)     11,333       12,879  
Loss on debt extinguishment           6,222  
Restructuring charges related to reduction in workforce (1)     4,876        
Non-GAAP net loss   $ (59,520 )   $ (76,983 )
             
GAAP net loss per share, basic and diluted   $ (0.96 )   $ (1.24 )
Non-GAAP net loss per share, basic and diluted   $ (0.75 )   $ (1.00 )
Shares used in computing basic and diluted net loss per share     79,268,853       77,253,699  

__________________________________
(1) In the quarter ended March 31, 2023, stock-based compensation of $1.0 million was classified within Restructuring charges related to reduction in workforce.



Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

IND cleared and enrolling patients in SC291 Phase 1 clinical trial in B-cell malignancies with initial data expected later this year

SC291 granted Fast Track Designation by the FDA for the treatment of relapsed/refractory large B-cell lymphoma and relapsed/refractory chronic lymphocytic leukemia

Expect data later this year from investigator-sponsored trial with hypoimmune-modified primary human islet cells

Goal to submit INDs this year for both SC262 and SG299 in hematologic cancers

Strengthened R&D leadership with addition of Dr. Doug Williams as President of Research and Development and Dr. Gary Meininger as Chief Medical Officer

Publication in Nature Communications demonstrates immune evasion, persistence, and anti-tumor activity of hypoimmune-modified CD19-directed CAR T cells in allogeneic humanized mouse model

Publication in Science Translational Medicine highlights multiple preclinical datasets for hypoimmune-modified islet cells

demonstrating potential for allogeneic immune evasion, autoimmune evasion, and control of type 1 diabetes

Publication in Nature Biotechnology shows that hypoimmune-modified allogeneic cells survive and escape immune detection while remaining fully functional across several species, including non-human primates with normal immune systems

Presented multiple abstracts from hypoimmune and fusogen platforms at 2023 AACR meeting

Cash position of $355 million expected to support activities through multiple data readouts and last into 2025

SEATTLE, May 08, 2023 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today reported financial results and business highlights for the first quarter 2023.

“Our initial human studies using Sana’s hypoimmune technology remain on track, as we have begun enrolling patients in our SC291 trial and expect to deliver data from two clinical studies in 2023,” said Steve Harr, Sana’s President and Chief Executive Officer. “We are also making progress in our earlier-stage pipeline and are on pace to file two additional INDs later this year and potentially three more in 2024. The quality of our key hires, publications in high quality peer-reviewed journals, and presentations at important scientific conferences are recent validations of the science behind Sana’s programs. Our capital position and people give us the resources for multiple data read-outs with our current balance sheet, and we continue to be optimistic about our future, with the opportunity to see the potential of these medicines in patients starting this year.”

Recent Corporate Highlights

Opportunity for clinical proof of concept for two different first-in-human studies, each with the potential for initial clinical data this year

  • SC291 is an ex vivo hypoimmune-modified CD19-directed allogeneic CAR T cell therapy. The goal of the hypoimmune platform is to overcome the immunologic rejection of allogeneic cells, which, if successful with SC291, may result in longer CAR T cell persistence and a higher rate of durable complete responses for patients with B-cell malignancies.
    • Received clearance from the Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 study of SC291 in patients with B-cell malignancies (ARDENT).
    • Began enrollment in the ARDENT Phase 1 study.
    • Granted Fast Track Designation for SC291 by the FDA for the treatment of relapsed/refractory (r/r) large B-cell lymphoma and r/r chronic lymphocytic leukemia.
    • SC291 has the potential to serve as clinical proof-of-platform for other hypoimmune-modified CAR T cell candidates using validated CAR constructs in development at Sana for hematological malignancies, such as SC262 (CD22) and SC255 (BCMA). Sana’s goal is to file INDs for SC262 later this year and SC255 in 2024.
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes. SC451, which is engineered with Sana’s hypoimmune technology, has the potential to replace missing islet cells without immunosuppression in persons with type 1 diabetes by evading allogeneic and autoimmune responses.
    • Expect initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients. The goal of the study is to show cell survival and immune evasion without the need for any immunosuppression.
    • Sana’s goal is to file an IND for SC451 in 2024.

Published preclinical data in

Nature Communications

describing immune evasion, persistence, and durable anti-tumor activity of Sana’s hypoimmune-modified CD19-directed CAR T cells

  • Sana developed hypoimmune-modified CD19 targeted allogeneic CAR T cells and compared them to unmodified CD19-targeted allogeneic CAR T cells in a murine leukemia model with a humanized immune system.
  • Although both hypoimmune-modified and unmodified CAR T cells showed robust early tumor killing, cell durability was much greater in humanized mice treated with hypoimmune-modified cells. Hypoimmune-modified allogeneic CAR T cells persisted and removed all evidence of tumor for the duration of the study. Hypoimmune-modified CAR T cells also cleared all evidence of tumor after re-injection with cancer cells 90 days into the study. In contrast and consistent with the experience in patients to date, unmodified allogeneic CAR T cells show greatly reduced persistence and a high rate of tumor recurrence in this model.
  • These studies provide additional insight for SC291 and the allogeneic hypoimmune CAR T platform more broadly, including SC262 and SC255.

Published preclinical data in

Science Translational Medicine

demonstrating that Sana’s hypoimmune-modified pseudo-islets control type 1 diabetes

  • Sana developed hypoimmune-modified human islet cells, which cluster into effective endocrine organoids termed “pseudo islets” (p-islets) and studied these p-islets in multiple preclinical models.
  • Preclinical data showed that p-islets survive, persist, escape allogeneic rejection, and normalize blood glucose in diabetic models with humanized immune systems.
  • Two different murine models showed that the hypoimmune-modified cells can evade autoimmune rejection and normalize blood glucose. First, these cells were studied in the NOD mouse model, which is the standard model for autoimmunity in diabetes. Second, Sana created a humanized mouse model with immune cells from a diabetic person and transplanted pancreatic islet cells derived from the diabetic person’s stem cells. In both cases, unmodified pancreatic islet cells were rapidly cleared by the immune system. In contrast, hypoimmune-modified pancreatic islet cells survived, persisted, and provided sustained blood glucose control in both models.
  • These studies provide additional insight for SC451 in persons with type 1 diabetes.

Published preclinical data in

Nature Biotechnology

demonstrating that Sana’s hypoimmune-modified cells survive allogeneic transplant across several species, including non-human primates (NHPs) with normal immune systems, and remain fully functional

  • Sana developed hypoimmune-modified NHP induced pluripotent stem cells (iPSCs) and transplanted them into immune-competent NHPs. Results were compared to transplantation of unmodified iPSCs into immune-competent NHPs.
  • Data showed that hypoimmune-modified iPSCs survived for the duration of the study (16 weeks), while unmodified iPSCs disappeared within two weeks. There was an antibody and T cell response directed toward unmodified cells, but not hypoimmune-modified cells.
  • Hypoimmune-modified primary NHP pancreatic islet cells survived 40 weeks (duration of the study) after allogeneic transplantation into an immune-competent NHP versus less than one week for unmodified primary islet cells.
  • Hypoimmune-modified iPSCs were differentiated into pancreatic islet cells. Transplantation of hypoimmune-modified iPSC-derived pancreatic cells into allogeneic diabetic mice with a humanized immune system showed immune evasion after transplantation for the duration of the studies (4 weeks) and amelioration of diabetes and normalization of blood glucose levels.

Presented multiple abstracts at the 2023 American Association for Cancer Research (AACR) Annual Meeting highlighting

ex vivo

hypoimmune-modified allogeneic CAR T cells, as well as

in vivo

cell-specific delivery of genetic material using Sana’s

in vivo

fusogen platform

  • Presented preclinical data demonstrating that hypoimmune-modified CAR T cells provide lasting tumor control in immunocompetent allogeneic humanized mice even with tumor re-challenge.
  • Presented preclinical data in a late-breaking poster presentation demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR transgene delivery to resting primary T cells.
  • Presented preclinical data demonstrating the effectiveness of Sana’s fully human CD19 CAR delivered by CD8-targeted fusosomes in tumor killing assays. These fusosomes led to similar levels of tumor control as ex vivo generated CD19 CAR T cells.
  • Presented preclinical data demonstrating increased potency of CD8-targeted fusosomes delivering a CD19 CAR with pre-treatment of resting T cells with IL-7, rapamycin, or both. Pre-treatment with these molecules led to increased anti-tumor efficacy through increased T cell transduction and greater CAR T cell expansion.

Strengthened Research and Development leadership with the appointment of two seasoned drug developers

  • Appointed Doug Williams, Ph.D., as President of Research and Development. Dr. Williams has over 30 years of experience leading R&D organizations – including at Biogen, Seattle Genetics (now Seagen), Amgen, and Immunex – and over the course of his career has participated in the development of over a dozen approved drugs including multiple blockbusters.
  • Appointed Gary Meininger, M.D., as Chief Medical Officer. Dr. Meininger has approximately 20 years of experience in drug development. Most recently, he was at Vertex as Senior Vice President, Head of Clinical Development for Vertex Cell and Genetic Therapies and previously was at Janssen and Merck. Dr. Meininger is currently the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

First Quarter 2023 Financial Results

GAAP Results

  • Cash Position: Cash, cash equivalents, and marketable securities as of March 31, 2023 were $355.1 million compared to $434.0 million as of December 31, 2022. The decrease of $78.9 million was primarily driven by cash used in operations of $79.2 million and cash used for the purchase of property and equipment of $2.2 million. Cash used in operations includes multiple cash payments that will not recur this year. In addition, our cash balance will increase by $6.1 million in July 2023 as the letter of credit related to the Fremont facility reduces from $6.7 million to $0.6 million in July 2023.

  • Research and Development Expenses: For the three months ended March 31, 2023, research and development expenses, inclusive of non-cash expenses, were $67.2 million compared to $72.7 for the same period in 2022. The decrease of $5.5 million was primarily due to a decline in costs to acquire technology, laboratory supplies, third-party manufacturing costs, and other research costs. These decreases were partially offset by increased clinical development costs, personnel-related costs, operating costs for our manufacturing facility in Bothell, Washington, and other allocated costs. Research and development expenses include non-cash stock-based compensation of $6.0 million and $5.7 million, for the three months ended March 31, 2023 and 2022, respectively.

  • Research and Development Related Success Payments and Contingent Consideration: For the three months ended March 31, 2023, we recognized an expense of $0.1 million and a gain of $55.4 million for the same period in 2022, in connection with the change in the estimated fair value of the success payment liabilities and contingent consideration in aggregate. The value of these potential liabilities may fluctuate significantly with changes in Sana’s market capitalization and stock price.

  • General and Administrative Expenses: General and administrative expenses for the three months ended March 31, 2023, inclusive of non-cash expenses, were $16.8 million compared to $14.4 million for the same period in 2022. The increase of $2.4 million was primarily due to operating costs for the previously planned manufacturing facility, formerly in research and development expense, and increased non-cash stock-based compensation and personnel-related expenses. General and administrative expenses include non-cash stock-based compensation of $2.8 million and $2.0 million, for the three months ended March 31, 2023 and 2022, respectively.

  • Net Loss: Net loss for the three months ended March 31, 2023 was $82.1 million, or $0.43 per share, compared to $31.4 million, or $0.17 per share, for the same period in 2022.

Non-GAAP Measures

  • Non-GAAP Operating Cash Burn: Non-GAAP operating cash burn for the three months ended March 31, 2023 was $74.8 million compared to $82.0 million for the same period in 2022. Non-GAAP operating cash burn is the decrease in cash, cash equivalents, and marketable securities, excluding cash inflows from financing activities, cash outflows from business development and non-recurring restructuring activities, and the purchase of property and equipment.

  • Non-GAAP Net Loss: Non-GAAP net loss for the three months ended March 31, 2023 was $82.0 million, or $0.43 per share, compared to $86.9 million, or $0.47 per share, for the same period in 2022. Non-GAAP net loss excludes non-cash expenses related to the change in the estimated fair value of contingent consideration and success payment liabilities.

A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco, and Rochester.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the company’s vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its preclinical, clinical and regulatory development plans and timing expectations, including the expected timing of IND filings and clinical trials for the Company’s product candidates and indications for which such INDs will be filed, and expected timing, substance, and impact of data from clinical trials of its product candidates and an investigator-sponsored trial utilizing hypoimmune-modified primary human islet cells in type 1 diabetes patients (the “IST”); expectations regarding the IST, including the ability to initiate the IST and the potential of the IST to show cell survival and immune evasion without immunosuppression; the potential ability of SC291 to serve as clinical proof-of-platform for other hypoimmune-modified CAR T cell candidates; expectations with respect to the potential therapeutic benefits and impact of its development programs and platforms, including the potential ability of the hypoimmune platform to overcome immunologic rejection of allogeneic cells and the impact thereof, the potential for hypoimmune-modified islet cells to demonstrate allogeneic immune evasion, autoimmune evasion, and control of type 1 diabetes, and the potential ability to replace missing islet cells without immunosuppression in patients with type 1 diabetes; the potential ability of preclinical data to provide insight for the Company’s development programs and platforms; expectations regarding the Company’s capital position, resources, and balance sheet and the potential impact thereof on the Company’s development programs, including data readouts from such programs; expectations regarding the impact of a reduction in the amount of the letter of credit for the Company’s Fremont, California facility on the Company’s cash balance; and the potential impact of changes in the Company’s market capitalization and stock price on its potential success payment and contingent consideration liabilities. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market, and social disruptions, including due to the COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s Securities and Exchange Commission (SEC) reports, including but not limited to its Quarterly Report on Form 10-Q dated May 8, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media:
Nicole Keith
[email protected] 
[email protected] 

Sana Biotechnology, Inc.
Unaudited Selected Consolidated Balance Sheet Data
 
    March 31, 2023     December 31, 2022  
       
    (in thousands)  
Cash, cash equivalents, and marketable securities   $ 355,131     $ 434,014  
Total assets     746,928       822,720  
Contingent consideration     155,839       150,379  
Success payment liabilities     15,667       21,007  
Total liabilities     318,666       323,405  
Total stockholders’ equity     428,262       499,315  

Sana Biotechnology, Inc.
Unaudited Consolidated Statements of Operations
 
    Three Months Ended March 31,  
    2023     2022  
     
  (in thousands, except per share data)  
Operating expenses:                
Research and development   $ 67,166     $ 72,689  
Research and development related success payments and contingent consideration     120       (55,438 )
General and administrative     16,766       14,434  
Total operating expenses     84,052       31,685  
Loss from operations     (84,052 )     (31,685 )
Interest income, net     1,976       339  
Other expense, net     (47 )     (102 )
Net loss   $ (82,123 )   $ (31,448 )
Net loss per common share – basic and diluted   $ (0.43 )   $ (0.17 )
Weighted-average number of common shares – basic and diluted     191,228       185,955  

Sana Biotechnology, Inc.
Changes in the Estimated Fair Value of Success Payments and Contingent Consideration
 
    Success Payment

Liability

(


1)
    Contingent

Consideration

(


2)
    Total Success
Payment Liability
and Contingent 
Consideration
 
    (in thousands)  
Liability balance as of December 31, 2022   $ 21,007     $ 150,379     $ 171,386  
Changes in fair value – expense (gain)     (5,340 )     5,460       120  
Liability balance as of March 31, 2023     15,667       155,836       171,506  
Total change in fair value for the three months ended March 31, 2023   $ (5,340 )   $ 5,460     $ 120  

(1)   Cobalt Biomedicine, Inc. (Cobalt) and the Presidents of Harvard College (Harvard) are entitled to success payments pursuant to the terms and conditions of their respective agreements. The success payments are recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.
(2)   Cobalt is entitled to contingent consideration upon the achievement of certain milestones pursuant to the terms and conditions of the agreement. Contingent consideration is recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with generally accepted accounting principles in the United States (GAAP), Sana uses certain non-GAAP financial measures to evaluate its business. Sana’s management believes that these non-GAAP financial measures are helpful in understanding Sana’s financial performance and potential future results, as well as providing comparability to peer companies and period over period. In particular, Sana’s management utilizes non-GAAP operating cash burn, non-GAAP research and development expense and non-GAAP net loss and net loss per share. Sana believes the presentation of these non-GAAP measures provides management and investors greater visibility into the Company’s actual ongoing costs to operate its business, including actual research and development costs unaffected by non-cash valuation changes and certain one-time expenses for acquiring technology, as well as facilitating a more meaningful comparison of period-to-period activity. Sana excludes these items because they are highly variable from period to period and, in respect of the non-cash expenses, provides investors with insight into the actual cash investment in the development of its therapeutic programs and platform technologies.

These are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Sana’s financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting. Sana’s management uses these supplemental non-GAAP financial measures internally to understand, manage, and evaluate Sana’s business and make operating decisions. In addition, Sana’s management believes that the presentation of these non-GAAP financial measures is useful to investors because they enhance the ability of investors to compare Sana’s results from period to period and allows for greater transparency with respect to key financial metrics Sana uses in making operating decisions. The following are reconciliations of GAAP to non-GAAP financial measures:

Sana Biotechnology, Inc.
Unaudited Reconciliation of Change in Cash, Cash Equivalents, and Marketable Securities to
Non-GAAP Operating Cash Burn
 
    Three Months Ended March 31,  
    2023     2022  
     
  (in thousands)  
Beginning cash, cash equivalents, and marketable securities   $ 434,014     $ 746,877  
Ending cash, cash equivalents, and marketable securities     355,131       657,392  
Change in cash, cash equivalents, and marketable securities     (78,883 )     (89,485 )
Cash paid to purchase property and equipment     2,176       7,533  
Change in cash, cash equivalents, and marketable securities, excluding capital expenditures     (76,707 )     (81,952 )
Adjustments:                
Cash paid for restructuring(1)     1,881        
Operating cash burn – Non-GAAP   $ (74,826 )   $ (81,952 )

(1)   The non-GAAP adjustment of $1.9 million for the three months ended March 31, 2023 consisted of cash payments related to the portfolio prioritization and corporate restructuring in the fourth quarter of 2022.

Sana Biotechnology, Inc.
Unaudited Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss Per Share
 
    Three Months Ended March 31,  
    2023     2022  
       
    (in thousands, except per share data)  
Net loss – GAAP   $ (82,123 )   $ (31,448 )
Adjustments:                
Change in the estimated fair value of the success payment liabilities(1)     (5,340 )     (54,910 )
Change in the estimated fair value of contingent consideration(2)     5,460       (528 )
Net loss – Non-GAAP   $ (82,003 )   $ (86,886 )
Net loss per share – GAAP   $ (0.43 )   $ (0.17 )
Adjustments:                
Change in the estimated fair value of the success payment liabilities(1)     (0.03 )     (0.30 )
Change in the estimated fair value of contingent consideration(2)     0.03        
Net loss per share – Non-GAAP   $ (0.43 )   $ (0.47 )
Weighted-average shares outstanding – basic and diluted     191,228       185,955  

(1)   For the three months ended March 31, 2023, the gains related to the Cobalt and Harvard success payment liabilities were $4.8 million and $0.6 million, respectively, compared to gains of $46.8 million and 8.1 million, respectively, for the same periods in 2022.
(2)   The contingent consideration is in connection with the acquisition of Cobalt.



ForgeRock Announces First Quarter 2023 Financial Results

ForgeRock Announces First Quarter 2023 Financial Results

  • ARR was $238 million for Q1 2023, growing 23% year-over-year

  • Total revenue was $63.1 million in Q1 2023, growing 31% year-over-year

  • Subscription SaaS, support & maintenance revenue was $34.1 million Q1 2023, growing 30% year-over-year

SAN FRANCISCO–(BUSINESS WIRE)–
ForgeRock, Inc. (NYSE: FORG), a global leader in digital identity, today announced financial results for its first quarter ended March 31, 2023.

“We ended Q1 with $238 million of ARR, representing another solid quarter of growth for ForgeRock,” said Fran Rosch, CEO of ForgeRock. “Adoption of the ForgeRock Identity Cloud continued to be strong, with these new SaaS customers representing the majority of our new ARR and new logos in the quarter. The introduction of Enterprise Connect Passwordless is another major step forward in enabling our customers to deliver digital experiences that simply and safely help people access the connected world. ForgeRock’s unique platform offers a full spectrum of passwordless capabilities designed for all users, including workforce, consumer, and partners.”

“Our revenue grew 31% year-over-year in Q1 and our gross margin continues to be robust and consistent at 81% on a GAAP basis and 83% on a non-GAAP basis,” said John Fernandez, CFO of ForgeRock. “We remain laser focused on balancing innovation and new business growth with cost management and profitability. Our GAAP operating margin was (40)% in Q1 and includes the impact of acquisition-related costs, and (32)% in Q1 of the prior year. Our non-GAAP operating margin in Q1 of (13)% was a significant improvement over the (19)% we experienced in Q1 of the prior year.”

First Quarter 2023 Financial Highlights:

  • ARR: Annualized Recurring Revenue was $238 million, an increase of 23% year-over-year.
  • Revenue: Total revenue was $63.1 million, an increase of 31% year-over-year.
  • Operating Loss: GAAP operating loss was $25.1 million, or 40% of total revenue, compared to $15.6 million, or 32% of total revenue, in the first quarter of 2022. Non-GAAP operating loss was $8.0 million, or 13% of total revenue, compared to $9.2 million, or 19% of total revenue, in the first quarter of 2022.
  • Net Loss: GAAP net loss was $25.4 million, compared to $16.5 million in the first quarter of 2022. GAAP net loss per share was $0.29, compared to $0.20 in the first quarter of 2022. Non-GAAP net loss was $8.2 million, compared to $9.9 million in the first quarter of 2022. Non-GAAP net loss per share was $0.09, compared to $0.12 in the first quarter of 2022.
  • Cash Flow: Net cash used in operations was $4.3 million, compared to $4.5 million in the first quarter of 2022. Free cash flow was $(4.6) million, or (7)% of total revenue, compared to $(5.0) million, or (10)% of total revenue, in the first quarter of 2022.
  • Cash, cash equivalents and short-term investments were $335.7 million as of March 31, 2023.

ForgeRock uses certain non-GAAP financial measures, which are described further below and reconciled to the most comparable GAAP financial measure after the presentation of our GAAP financial statements.

Transaction with Thoma Bravo

As previously reported, the U.S. Department of Justice (the “DOJ”) has issued a Second Request in connection with its review of the proposed acquisition of ForgeRock by Thoma Bravo pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”). In February 2023, ForgeRock and entities affiliated with Thoma Bravo entered into an agreement (the “Timing Agreement”) with the DOJ in connection with the proposed acquisition and the Second Request. Under the Timing Agreement, ForgeRock and Thoma Bravo agreed that they will certify compliance with the Second Request no earlier than May 1, 2023, and will not consummate the proposed acquisition less than 75 days after compliance with the Second Request. The Timing Agreement does not prevent ForgeRock and Thoma Bravo from consummating the proposed acquisition sooner if the DOJ closes its investigation of the proposed acquisition before that date. The expiration or termination of the waiting period applicable to the proposed acquisition pursuant to the HSR Act (and the absence of any agreement with any governmental authority not to consummate the proposed acquisition) is the only remaining approval or regulatory condition required to consummate the closing of the proposed acquisition.

Due to the Company’s pending acquisition by Thoma Bravo that was announced on October 11, 2022, there will not be a conference call or live webcast to discuss these financial results. In addition, the Company has suspended its financial guidance as a result of the pending transaction.

Non-GAAP Financial Measures and Key Metrics:

Besides financial results prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), ForgeRock believes that evaluating its ongoing operating results may be difficult if limited to reviewing only GAAP financial measures. Accordingly, ForgeRock uses non-GAAP financial measures to evaluate its operations. We use non-GAAP financial measures to understand and evaluate our core operating performance and trends, to prepare our annual budget, to monitor and assess our liquidity, and to develop short-term and long-term operating plans. We believe that the non-GAAP financial measures we review are each a useful measure to us and to our investors because they provide consistency and comparability with our past performance and between periods, as these metrics generally eliminate the effects of the variability of certain charges and expenses that may not reflect our overall operating performance and liquidity. We believe that non-GAAP financial measures, when taken collectively with GAAP financial information, can be helpful to us and to investors because it provides consistency and comparability with past performance and assists in comparisons with other companies, some of which use similar non-GAAP financial information to supplement their GAAP results.

ForgeRock presents non-GAAP gross profit, non-GAAP gross margin, non-GAAP research and development, non-GAAP sales and marketing, non-GAAP general and administrative, non-GAAP operating loss, non-GAAP operating margin and non-GAAP net loss per share, all of which exclude acquisition-related costs, stock-based compensation expense, and certain of which exclude the tax effect on the provision for (benefit from) income taxes related to such excluded items. ForgeRock excludes acquisition-related costs because they are unrelated to our current operations and are neither comparable to the prior period nor indicative of future results. We also exclude stock-based compensation expense as it can vary significantly from period to period based on share price and the timing, size and nature of equity awards. As such, ForgeRock and many investors and analysts exclude stock-based compensation expense to better evaluate its operating performance and cash spending levels relative to its industry sector and competitors.

ForgeRock presents adjusted EBITDA, which is also a non-GAAP financial measure. We define adjusted EBITDA as GAAP operating loss, adjusted for depreciation, acquisition-related costs and stock-based compensation expense. ForgeRock excludes certain items that it believes are not good indicators of ForgeRock’s current or future operating performance. These items are depreciation, acquisition-related costs and stock-based compensation. ForgeRock excludes depreciation given its standard exclusion in EBITDA and adjusted EBITDA results. In addition, the frequency and amount of such charges can vary significantly based on the size and timing of the transactions.

ForgeRock also presents free cash flow, which is a non-GAAP financial measure. We define free cash flow as net cash used in operating activities less cash used for purchases of property and equipment. ForgeRock provides free cash flow as it is a commonly used non-GAAP financial measure to indicate the amount of cash needed to fund its operations and capital expenditures.

The non-GAAP financial information is presented for supplemental informational purposes only and should not be considered a substitute for financial information presented in accordance with GAAP and may be different from similarly-titled non-GAAP measures used by other companies. The principal limitation of these non-GAAP financial measures is that they exclude expenses that are required by GAAP to be recorded in our consolidated financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by our management about which expenses are excluded or included in determining these non-GAAP financial measures. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures.

ForgeRock also uses the key metric Annualized Recurring Revenue (“ARR”), to evaluate its operations. We believe that ARR is a key metric because it is driven by our ability to acquire new customers and to maintain and expand our relationship with existing customers. We define ARR as the annualized value of all contractual subscription agreements as of the end of the period. To the extent that we are negotiating a renewal with a customer after the expiration of the subscription, we continue to include that revenue in ARR if we are actively in discussion with such an organization for a new subscription or renewal, or until such organization notifies us that it is not renewing its subscription. We perform this calculation on an individual customer basis by dividing the total dollar amount of the customer’s contract by the total contract term stated in months and multiplying this amount by 12 to annualize. Calculated ARR for each individual customer is then aggregated to arrive at total ARR.

ARR does not have a standardized meaning and therefore may not be comparable to similarly titled measures presented by other companies. ARR should be viewed independently of revenue, deferred revenue and remaining performance obligations computed and/or disclosed in accordance with GAAP and is not intended to be combined with or to replace any of those items. Specifically, ARR, as calculated under the definition herein, has the effect of normalizing the impact of revenue recognition for term-based subscription license agreements. ARR is calculated based upon annualized contract value and not actual GAAP revenue. Under ASC 606, for term-based subscription license agreements, we recognize approximately half of the total contract value upfront as license revenue, with the remainder attributable to maintenance and support that is recognized ratably over the license term. Annualizing actual GAAP revenue for any particular period could result in a meaningful difference from our ARR calculation, particularly when we are experiencing increases or decreases in the mix of multi-year term licenses. ARR is not a forecast and the active contracts at the date used in calculating ARR may or may not be extended by our customers.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or ForgeRock’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or the negative of these words or other similar terms or expressions that concern ForgeRock’s expectations, strategy, priorities, plans or intentions. Forward-looking statements in this release include, but are not limited to the quotations of management, statements regarding the proposed acquisition by entities affiliated with Thoma Bravo, our strategy, products, including new offerings and the capabilities of our platform, and financial condition. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to the pendency of the proposed acquisition by entities affiliated with Thoma Bravo or the failure to complete such transaction, our ability to attract new customers and retain and sell additional functionality and services to our existing customers, our ability to sustain and manage our growth, our ability to successfully add new features and functionality to our platform, our ability to compete effectively in an increasingly competitive market, and general market, political, economic, and business conditions, and other risks detailed in our filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K filed with the SEC on March 1, 2023 and in our Quarterly Report on Form 10-Q that will be filed with the SEC on or about May 9, 2023.

Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. We anticipate that subsequent events and developments could cause our views to change. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About ForgeRock

ForgeRock®, a global leader in digital identity, delivers modern identity and access management solutions for consumers, employees and things to simply and safely access the connected world. Using ForgeRock, more than 1,300 organizations around the world orchestrate, manage, and secure the complete lifecycle of identities from dynamic access controls, governance, APIs, and storing authoritative data – consumable in cloud or hybrid environments.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

(In thousands, except per share amounts)

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

Revenue:

 

 

 

Subscription term licenses

$

25,557

 

 

$

19,659

 

Subscription SaaS, support & maintenance

 

34,101

 

 

 

26,185

 

Perpetual licenses

 

65

 

 

 

86

 

Total subscriptions and perpetual licenses

 

59,723

 

 

 

45,930

 

Professional services

 

3,420

 

 

 

2,163

 

Total revenue

 

63,143

 

 

 

48,093

 

Cost of revenue:

 

 

 

Subscriptions and perpetual licenses

 

8,322

 

 

 

5,853

 

Professional services

 

3,478

 

 

 

2,850

 

Total cost of revenue

 

11,800

 

 

 

8,703

 

Gross profit

 

51,343

 

 

 

39,390

 

Operating expenses:

 

 

 

Research and development

 

17,203

 

 

 

14,479

 

Sales and marketing

 

36,451

 

 

 

26,978

 

General and administrative

 

15,868

 

 

 

13,545

 

Acquisition-related costs

 

6,947

 

 

 

 

Total operating expenses

 

76,469

 

 

 

55,002

 

Operating loss

 

(25,126

)

 

 

(15,612

)

Foreign currency gain (loss)

 

(542

)

 

 

435

 

Interest expense

 

(1,135

)

 

 

(899

)

Other income, net

 

1,836

 

 

 

68

 

Interest and other income (expense), net

 

159

 

 

 

(396

)

Loss before income taxes

 

(24,967

)

 

 

(16,008

)

Provision for income taxes

 

469

 

 

 

462

 

Net loss

$

(25,436

)

 

$

(16,470

)

Net loss per share attributable to common stockholders:

 

 

 

Basic and diluted

$

(0.29

)

 

$

(0.20

)

Weighted-average shares used in computing net loss per share attributable to common stockholders:

 

 

 

Basic and diluted

 

87,463

 

 

 

83,766

 

(1) Includes stock-based compensation as follows (in thousands):

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

2022

 

 

 

 

Cost of revenue

$

1,005

 

$

517

Research and development

 

2,010

 

 

1,400

Sales and marketing

 

3,940

 

 

2,258

General and administrative

 

3,228

 

 

2,285

Total stock-based compensation expense

$

10,183

 

$

6,460

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(In thousands, except par value)

 

 

March 31,

2023

 

December 31,

2022

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

143,971

 

 

$

128,803

 

Short-term investments

 

191,743

 

 

 

207,248

 

Accounts receivable, net of allowance for credit losses of $664 and $444, respectively

 

47,097

 

 

 

71,439

 

Contract assets

 

27,203

 

 

 

25,117

 

Deferred commissions

 

9,480

 

 

 

9,936

 

Prepaid expenses and other assets

 

15,891

 

 

 

14,810

 

Total current assets

 

435,385

 

 

 

457,353

 

Deferred commissions

 

20,740

 

 

 

20,379

 

Property and equipment, net

 

2,922

 

 

 

2,850

 

Operating lease right-of-use assets

 

9,816

 

 

 

10,190

 

Contract and other assets

 

3,784

 

 

 

3,408

 

Total assets

$

472,647

 

 

$

494,180

 

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

8,564

 

 

$

4,587

 

Accrued compensation

 

15,735

 

 

 

24,836

 

Accrued expenses

 

8,649

 

 

 

9,475

 

Current portion of operating lease liability

 

1,941

 

 

 

1,902

 

Deferred revenue

 

78,315

 

 

 

82,036

 

Other liabilities

 

2,526

 

 

 

2,927

 

Total current liabilities

 

115,730

 

 

 

125,763

 

Long-term debt

 

39,643

 

 

 

39,611

 

Long-term operating lease liability

 

8,790

 

 

 

9,207

 

Deferred revenue

 

920

 

 

 

1,283

 

Other liabilities

 

2,585

 

 

 

2,150

 

Total liabilities

 

167,669

 

 

 

178,014

 

Stockholders’ equity

 

 

 

Common stock

 

88

 

 

 

87

 

Additional paid-in capital

 

654,600

 

 

 

641,983

 

Accumulated other comprehensive income

 

5,823

 

 

 

4,193

 

Accumulated deficit

 

(355,533

)

 

 

(330,097

)

Total stockholders’ equity

 

304,978

 

 

 

316,166

 

Total liabilities and stockholders’ equity

$

472,647

 

 

$

494,180

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(In thousands)

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

Operating activities:

 

 

 

Net loss

$

(25,436

)

 

$

(16,470

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation

 

256

 

 

 

280

 

Noncash operating lease expense

 

613

 

 

 

535

 

Stock-based compensation expense

 

10,183

 

 

 

6,460

 

Amortization of deferred commissions

 

3,916

 

 

 

3,991

 

Foreign currency remeasurement loss (gain)

 

552

 

 

 

(620

)

Amortization of premium / discount on short-term investments

 

(867

)

 

 

646

 

Other

 

421

 

 

 

102

 

Changes in operating assets and liabilities:

 

 

 

Deferred commissions

 

(3,822

)

 

 

(4,085

)

Accounts receivable

 

25,158

 

 

 

17,321

 

Contract and other non-current assets

 

(2,275

)

 

 

(122

)

Prepaid expenses and other current assets

 

(913

)

 

 

(893

)

Operating lease liabilities

 

(634

)

 

 

(499

)

Accounts payable

 

3,957

 

 

 

(436

)

Accrued expenses and other liabilities

 

(10,382

)

 

 

(4,640

)

Deferred revenue

 

(5,034

)

 

 

(6,040

)

Net cash used in operating activities

 

(4,307

)

 

 

(4,470

)

Investing activities:

 

 

 

Purchases of property and equipment

 

(285

)

 

 

(488

)

Purchases of short-term investments

 

(18,974

)

 

 

(52,994

)

Maturities of short-term investments

 

35,763

 

 

 

14,452

 

Sales of short-term investments

 

579

 

 

 

4,836

 

Net cash provided by (used in) investing activities

 

17,083

 

 

 

(34,194

)

Financing activities:

 

 

 

Proceeds from exercises of employee stock options

 

6,338

 

 

 

2,179

 

Payment of offering costs

 

 

 

 

(141

)

Employee payroll taxes paid for net shares settlement of restricted stock units

 

(3,903

)

 

 

 

Net cash provided by financing activities

 

2,435

 

 

 

2,038

 

Effect of exchange rates on cash and cash equivalents and restricted cash

 

(50

)

 

 

(200

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

15,161

 

 

 

(36,826

)

Cash, cash equivalents and restricted cash, beginning of year

 

131,324

 

 

 

128,437

 

Cash, cash equivalents and restricted cash, end of period

$

146,485

 

 

$

91,611

 

 

 

 

 

Reconciliation of cash and cash equivalents and restricted cash:

 

 

 

Cash and cash equivalents

$

143,971

 

 

$

91,580

 

Restricted cash included in prepaids and other current assets

 

2,514

 

 

 

31

 

Total cash and cash equivalents and restricted cash

$

146,485

 

 

$

91,611

 

FORGEROCK, INC.

NON-GAAP FINANCIAL MEASURES AND RECONCILIATIONS TO GAAP RESULTS

Non-GAAP Gross Profit and Non-GAAP Gross Margin

 

 

 

 

Gross profit is defined as GAAP revenue less cost of revenue and gross margin is GAAP gross profit as a percentage of total revenue. We define non-GAAP gross profit and non-GAAP gross margin as GAAP gross profit and GAAP gross margin adjusted to exclude stock-based compensation expense, as presented below (in thousands, except percentages):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Gross profit

$

51,343

 

 

$

39,390

 

Add: Stock-based compensation

 

1,005

 

 

 

517

 

Non-GAAP gross profit

$

52,348

 

 

$

39,907

 

 

 

 

 

Gross margin

 

81

%

 

 

82

%

Non-GAAP gross margin

 

83

%

 

 

83

%

 

 

 

 

Non-GAAP Research and Development

 

 

 

 

We define non-GAAP research and development as GAAP research and development adjusted to exclude stock-based compensation expense as presented below (in thousands):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Research and development

$

17,203

 

 

$

14,479

 

Less: Stock-based compensation

 

2,010

 

 

 

1,400

 

Non-GAAP research and development

$

15,193

 

 

$

13,079

 

 

 

 

 

Non-GAAP Sales and Marketing

 

 

 

 

We define non-GAAP sales and marketing as GAAP sales and marketing adjusted to exclude stock-based compensation expense as presented below (in thousands):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Sales and marketing

$

36,451

 

 

$

26,978

 

Less: Stock-based compensation

 

3,940

 

 

 

2,258

 

Non-GAAP sales and marketing

$

32,511

 

 

$

24,720

 

 

 

 

 

Non-GAAP General and Administrative

 

 

 

 

We define non-GAAP general and administrative as GAAP general and administrative adjusted to exclude stock-based compensation expense as presented below (in thousands):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

General and administrative

$

15,868

 

 

$

13,545

 

Less: Stock-based compensation

 

3,228

 

 

 

2,285

 

Non-GAAP general and administrative

$

12,640

 

 

$

11,260

 

 

 

 

 

Non-GAAP Operating Loss and Non-GAAP Operating Margin

 

 

 

 

We define non-GAAP operating loss and non-GAAP operating margin as GAAP operating loss and GAAP operating margin adjusted to exclude stock-based compensation expense and acquisition-related costs, as presented below (in thousands, except percentages):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Operating loss

$

(25,126

)

 

$

(15,612

)

Add: Stock-based compensation

 

10,183

 

 

 

6,460

 

Add: Acquisition-related costs

 

6,947

 

 

 

 

Non-GAAP operating loss

$

(7,996

)

 

$

(9,152

)

 

 

 

 

Operating margin

 

(40

) %

 

 

(32

) %

Non-GAAP operating margin

 

(13

) %

 

 

(19

) %

 

 

 

 

Adjusted EBITDA

 

 

 

 

We define adjusted EBITDA as operating loss adjusted to exclude depreciation, stock-based compensation expense and acquisition-related costs, as presented below (in thousands):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Operating loss

$

(25,126

)

 

$

(15,612

)

Add: Depreciation

 

256

 

 

 

280

 

Add; Stock-based compensation

 

10,183

 

 

 

6,460

 

Add: Acquisition-related costs

 

6,947

 

 

 

 

Adjusted EBITDA

$

(7,740

)

 

$

(8,872

)

 

 

 

 

Non-GAAP Net Loss and Non-GAAP Net Loss per Share, Basic and Diluted

 

 

 

 

We define non-GAAP net loss as GAAP net loss adjusted to exclude stock-based compensation expense and acquisition-related costs, including the tax effect of stock-based compensation expense on the provision for (benefit from) income taxes as presented below (in thousands, except per share amounts):

 

 

 

 

We define non-GAAP net loss per share, basic, as non-GAAP net loss divided by GAAP weighted-average shares used to compute net loss per share, basic.

 

 

 

 

We define non-GAAP net loss per share, diluted, as non-GAAP net loss divided by GAAP weighted average shares used to compute net loss per share, basic, adjusted for the dilutive effect of employee equity awards, excluding the impact of unrecognized stock-based compensation expense, unless these adjustments are anti-dilutive.

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Net loss

$

(25,436

)

 

$

(16,470

)

Add: Stock-based compensation

 

10,183

 

 

 

6,460

 

Add: Acquisition-related costs

 

6,947

 

 

 

 

Tax effect on the provision for income taxes

 

114

 

 

 

62

 

Non-GAAP net loss

$

(8,192

)

 

$

(9,948

)

 

 

 

 

Non-GAAP net loss per share, basic and diluted

$

(0.09

)

 

$

(0.12

)

 

 

 

 

Free Cash Flow

 

 

 

 

We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and equipment as presented below (in thousands):

 

 

 

 

 

Three months ended March 31,

 

 

2023

 

 

 

2022

 

 

 

 

 

Net cash used in operating activities

$

(4,307

)

 

$

(4,470

)

Purchases of property and equipment

 

(285

)

 

 

(488

)

Free cash flow

$

(4,592

)

 

$

(4,958

)

 

 

 

 

 

Investor Relations:

[email protected]

Media Contacts:

Kristen Batch, ForgeRock

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Internet Security Data Management Technology Software

MEDIA:

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV

+

) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

Enrollment into fifth dose level in the dose escalation portion of the Phase 1b/2 trial of Nana-val in advanced EBV

+

solid tumors underway; data from complete dose escalation portion expected in 2H 2023

Cash, cash equivalents and investments of $80.3 million as of March 31, 2023 provides anticipated cash runway into late 2024

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced financial results for the first quarter of 2023 and recent clinical program updates.

“With progress from both of our clinical programs accelerating, we have the opportunity to achieve several important milestones this year. NAVAL-1 is enrolling at a rapid pace, and we look forward to readouts across multiple subtypes that could trigger our first advancement into Stage 2 in the months ahead,” said Mark Rothera, President and Chief Executive Officer of Viracta. “On the solid tumor front, we are currently seeking to optimize the dose of Nana-val and are pleased to see that its safety profile continues to support further dose escalation into our trial’s fifth dose level. Following the completion of the Phase 1b portion of the trial, we look forward to selecting our recommended Phase 2 dose and advancing our efforts around Nana-val as a potential tumor agnostic therapy for EBV-associated cancers.”

Program Highlights and Anticipated Milestones


Pivotal NAVAL-1 trial of Nana-val in relapsed/refractory (R/R) EBV



+



lymphoma

  • NAVAL-1 continues to enroll across each of the trial’s lymphoma subtype cohorts with more than 70 sites open globally.
  • An update on NAVAL-1’s first lymphoma subtype that may advance from Stage 1 to Stage 2 is anticipated in the second quarter of 2023.
  • Potential for additional update(s) on other NAVAL-1 lymphoma subtype(s) in the second half of 2023.


Phase 1b/2 trial of Nana-val in patients with recurrent/metastatic (R/M) EBV



+



nasopharyngeal carcinoma (NPC) and other advanced EBV



+



solid tumors

  • The trial has advanced into the fifth dose level of the Phase 1b dose escalation portion; no dose-limiting toxicities have been reported to date.
  • Clinical data previously reported across the first three dose levels (n=10) include one confirmed partial response (PR) at the third dose level and three patients achieving stable disease.
  • The Company remains on track to report complete Phase 1b dose escalation data and select a recommended Phase 2 dose (RP2D) in the second half of 2023.
  • Initiation of the trial’s Phase 2 randomized expansion cohort designed to evaluate Nana-val at the RP2D with or without pembrolizumab in patients with R/M EBV+ NPC is expected in the second half of 2023.
  • Initiation of the trial’s exploratory Phase 1b expansion cohort designed to evaluate Nana-val at the RP2D in patients with other advanced EBV+ solid tumors, including gastric carcinoma, leiomyosarcoma and lymphoepithelioma, is expected in the second half of 2023.

First Quarter 2023 Financial Results

  • Cash position – Cash, cash equivalents and short-term investments totaled approximately $80.3 million as of March 31, 2023, which Viracta expects will be sufficient to fund its operations into late 2024 excluding any additional borrowing under a $50.0 million credit facility, of which $25.0 million remains available, at the Company’s request, subject to the discretion of the lenders.
  • Research and development expenses – Research and development expenses were approximately $7.6 million for the three months ended March 31, 2023, compared to approximately $6.1 million for the three months ended March 31, 2022. The increase in research and development expenses was primarily driven by increases in costs incurred to support the advancement and expansion of our clinical development programs, including incremental costs to support NAVAL-1, our pivotal trial in R/R EBV+ lymphoma, and the initiation of our Phase 1b/2 trial for the treatment of EBV+ solid tumors, as well as an increase in personnel-related costs.
  • General and administrative expenses – General and administrative expenses were approximately $4.6 million for the three months ended March 31, 2023, compared to $4.3 million for the same period in 2022. The increase in general and administrative expenses can be attributed to an increase in personnel-related costs.
  • Net loss – Net loss was approximately $12.2 million, or $0.32 per share, (basic and diluted) for the quarter ended March 31, 2023, compared to a net loss of $10.5 million, or $0.28 per share (basic and diluted) for the same period in 2022.

About NAVAL-1

NAVAL-1 (NCT05011058) is a global, multicenter trial of Nana-val in R/R EBV+ lymphoma. The trial employs a Simon two-stage design where participants are enrolled into six indication cohorts based on EBV+ lymphoma subtype in Stage 1. If a pre-specified activity threshold is reached within a lymphoma subtype in Stage 1 (n=10), additional patients will be enrolled in Stage 2 for a total of 21 patients. EBVlymphoma subtypes demonstrating promising activity in Stage 2 may be further expanded following discussion with regulators to potentially support registration.

About the Phase 1b/2 Trial of Nana-val in R/M EBV

+

 NPC and Other EBV

+

 Solid Tumors

This Phase 1b/2 trial (NCT05166577) is an open-label, multinational trial evaluating Nana-val alone and in combination with pembrolizumab. The Phase 1b dose escalation part is designed to evaluate safety and to determine the RP2D of Nana-val in patients with R/M EBV+ NPC. In Phase 2, up to 60 patients with R/M EBV+ NPC will be randomized to receive Nana-val at the RP2D with or without pembrolizumab to evaluate safety, overall response rate, and potential pharmacodynamic markers. Additionally, patients with other advanced EBV+ solid tumors will be enrolled to receive Nana-val at the RP2D in a Phase 1b dose expansion cohort.

About Nana-val (Nanatinostat and Valganciclovir)

Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor being developed by Viracta. Nanatinostat is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in Epstein-Barr virus (EBV)-associated malignancies. Nanatinostat is currently being investigated in combination with the antiviral agent valganciclovir as an all-oral combination therapy, Nana-val, in various subtypes of EBV-associated malignancies. Ongoing trials include a pivotal, global, multicenter, open-label Phase 2 basket trial in multiple subtypes of relapsed/refractory EBVlymphoma (NAVAL-1) as well as a multinational Phase 1b/2 trial in patients with EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide. Viracta’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is currently being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other advanced EBV+ solid tumors. Viracta is also pursuing the application of its “Kick and Kill” approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Forward Looking Statements

This communication contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the details, timeline and expected progress for Viracta’s ongoing and anticipated trials and updates regarding the same, including NAVAL- 1 and the Phase 1b/2 trial of Nana-val in EBV+ solid tumor and the sufficiency of current cash reserves to fund ongoing operations for the specified period. Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement  include, but are not limited to: Viracta’s ability to successfully enroll patients in and complete its ongoing and planned clinical trials; the timing of initiation of Viracta’s planned clinical trials; the timing of the availability of data from Viracta’s clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta’s product candidates; Viracta’s ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; and Viracta’s estimates regarding future expenses, capital requirements and need for additional financing in the future.

These risks and uncertainties may be amplified by the ongoing COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in Viracta’s reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.

Investor Relations Contact:

Ashleigh Barreto
Head of Investor Relations & Corporate Communications
Viracta Therapeutics, Inc.
[email protected]

SOURCE Viracta Therapeutics, Inc.

— Financial tables attached –

Viracta Therapeutics, Inc.
Selected Balance Sheet Highlights

(in thousands)
           
  March 31,


  December 31,


  2023
  2022
   
(Unaudited)
     
Cash, cash equivalents and short-term investments $ 80,332     $ 91,043  
Total assets $ 85,781     $ 95,991  
Total liabilities $ 34,668     $ 34,888  
Stockholders’ equity $ 51,113     $ 61,103  
           
Viracta Therapeutics, Inc.
Condensed Consolidated Statement of Operations and Comprehensive Loss

(in thousands except share and per share data)

(Unaudited)
           
  Three Months Ended March 31,


  2023
  2022
Operating expenses:          
Research and development $ 7,607     $ 6,096  
General and administrative   4,600       4,336  
Total operating expenses   12,207       10,432  
Loss from operations   (12,207 )     (10,432 )
Total other expense   (2 )     (114 )
Net loss   (12,209 )     (10,546 )
Unrealized gain on short-term investments   91        
Comprehensive loss   (12,118 )     (10,546 )
Net loss per share, basic and diluted $ (0.32 )   $ (0.28 )
Weighted-average common shares outstanding, basic and diluted   38,458,837       37,535,874  



Guild Holdings Company Reports First Quarter 2023 Results

Guild Holdings Company Reports First Quarter 2023 Results

  • Originations of $2.7 Billion
  • Net Revenue of $103.9 Million
  • Net Loss of $37.2 Million
  • Adjusted Net Loss of $2.5 Million
  • Return on Equity of (12.1)% and Adjusted ROE of (0.8)%
  • Gain on Sale Margin on Originations of 343 bps
  • Purchase Recapture Rate of 24%
  • Completed Acquisition Subsequent to Quarter-End Which Expanded Presence Across 45 States and Expanded Reverse Mortgage Division

SAN DIEGO–(BUSINESS WIRE)–
Guild Holdings Company (NYSE: GHLD) (“Guild” or the “Company”), a growth-oriented mortgage company that employs a relationship-based loan sourcing strategy to execute on its mission of delivering the promise of homeownership, today announced results for the first quarter ended March 31, 2023.

“Our first quarter results came in largely as expected as the mortgage industry continues to face pressure from higher interest rates and limited home inventory,” stated Mary Ann McGarry, Chief Executive Officer. “However, Guild’s differentiated strategy has allowed us to gain market share and, we believe, position us for accelerated growth as demand returns. In particular, we’re seeing the benefits of our focus on the purchase mortgage market, our new products to meet the evolving needs of buyers, and our network of loan officers with deep relationships. With our recent acquisitions we are further building our foundation to drive growth, and we anticipate gaining additional market share as the acquisitions are fully integrated and continue to ramp. In addition to the acquisitions expanding our retail footprint, they have extended our product capabilities including a reverse mortgage product which will further strengthen our offerings and help us to serve more borrowers nationwide. Furthermore, we’re maintaining a solid balance sheet and liquidity position, and will continue to seek selective opportunities to invest and best position Guild as the market normalizes. Looking ahead, we anticipate continued pressure in the near term, but expect some pickup in mortgage activity as we enter the traditional home sales season.”

First Quarter

2023

Highlights

 

Total in-house originations of $2.7 billion compared to $3.0 billion in the prior quarter

 

Originated 92% of closed loan origination volume from purchase business, compared to the Mortgage Bankers Association estimate of 80%

 

Net revenue of $103.9 million compared to $134.3 million in the prior quarter

 

Net loss of $37.2 million compared to $15.0 million in the prior quarter

 

Servicing portfolio unpaid principal balance of $79.9 billion as of March 31, 2023, up 1.3% compared to $78.9 billion as of December 31, 2022

 

Adjusted net loss and Adjusted EBITDA totaled $2.5 million and $1.1 million, respectively, compared to adjusted net loss and adjusted EBITDA of $0.1 million and $1.9 million, respectively, in the prior quarter

 

Return on equity of (12.1)% and adjusted return on equity of (0.8)%, compared to (4.8)% and 0.0%, respectively, in the prior quarter

First Quarter Summary

Please refer to “Key Performance Indicators” and “GAAP to Non-GAAP Reconciliations” elsewhere in this release for a description of the key performance indicators and definitions of the non-GAAP measures and reconciliations to the nearest comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

($ amounts in millions, except per share amounts)

1Q’23

4Q’22

%∆

Total in-house originations

$

2,701.4

$

2,975.9

(9)%

Gain on sale margin on originations (bps)

 

343

 

331

4%

Gain on sale margin on pull-through adjusted locked volume (bps)

 

284

 

351

(19)%

UPB of servicing portfolio (period end)

$

79,916.6

$

78,893.0

1%

Net revenue

$

103.9

$

134.3

(23)%

Total expenses

$

154.7

$

157.5

(2)%

Net loss

$

(37.2)

$

(15.0)

148%

Return on equity

 

(12.1) %

 

(4.8) %

153%

Adjusted net loss

$

(2.5)

$

(0.1)

NM

Adjusted EBITDA

$

1.1

$

1.9

(41)%

Adjusted return on equity

 

(0.8) %

 

— %

NM

Loss per share

$

(0.61)

$

(0.25)

148%

Diluted loss per share

$

(0.61)

$

(0.25)

148%

Adjusted loss per share

$

(0.04)

$

NM

Origination Segment Results

Origination segment net loss was $32.8 million in the first quarter compared to net loss of $26.6 million in the prior quarter primarily driven by lower origination volumes as a result of higher interest rates. Gain on sale margins on originations increased 12 bps quarter-over-quarter to 343 bps. Gain on sale margins on pull-through adjusted locked volume decreased 67 bps quarter-over-quarter to 284 bps and total pull-through adjusted locked volume was $3.3 billion compared to $2.8 billion in the prior quarter. The increase in pull-through adjusted volume, up 21% over originations, creates a negative timing impact for gain on sale on pull-through adjusted volume and is not indicative of future expected gain on sale margins.

($ amounts in millions)

1Q’23

4Q’22

%∆

Total in-house originations

$

2,701.4

$

2,975.9

(9)%

In-house originations # (000’s)

 

9

 

9

—%

Net revenue

$

93.6

$

101.5

(8)%

Total expenses

$

126.3

$

128.0

(1)%

Net loss allocated to origination

$

(32.8)

$

(26.6)

23%

Servicing Segment Results

Servicing segment net loss was $0.3 million in the first quarter compared to net income of $21.5 million in the prior quarter. The Company retained mortgage servicing rights (“MSRs”) for 87% of total loans sold in the first quarter of 2023.

Net revenue totaled $13.1 million compared to $34.8 million in the prior quarter primarily due to adjustments to the fair value of the Company’s MSRs. In the first quarter of 2023, fair value adjustments with respect to the Company’s MSRs totaled a loss of $54.9 million, compared to $29.9 million in the prior quarter. Guild’s purchase recapture rate was 24% in the first quarter of 2023, which reinforces the Company’s focus on customer service and synergistic business model.

($ amounts in millions)

1Q’23

4Q’22

%∆

UPB of servicing portfolio (period end)

$

79,916.6

$

78,893.0

1%

# Loans serviced (000’s) (period end)

 

328

 

324

1%

Loan servicing and other fees

$

60.1

$

58.0

4%

Valuation adjustment of MSRs

$

(54.9)

$

(29.9)

84%

Net revenue

$

13.1

$

34.8

(62)%

Total expenses

$

13.4

$

13.3

1%

Net (loss) income allocated to servicing

$

(0.3)

$

21.5

(101)%

Share Repurchase Program

During the three months ended March 31, 2023, the Company repurchased and subsequently retired 50,166 shares of Guild’s Class A common stock at an average purchase price of $11.26 per share. As of March 31, 2023, $13.9 million remained available for repurchase under the Company’s share repurchase program.

Balance Sheet and Liquidity Highlights

The Company’s operating cash position was $147.8 million as of March 31, 2023. The Company’s unutilized loan funding capacity was $1.2 billion, while the unutilized MSR lines of credit was $205.0 million, based on total committed amounts and borrowing base limitations. The Company’s leverage ratio was 0.9x, defined as total secured debt including funding divided by tangible stockholders’ equity.

(in millions)

March 31,

2023

December 31,

2022

Cash and cash equivalents

$

147.8

$

137.9

Mortgage servicing rights, net

$

1,112.2

$

1,139.5

Warehouse lines of credit

$

762.1

$

713.2

Notes payable

$

130.0

$

126.3

Total stockholders’ equity

$

1,213.3

$

1,249.3

Webcast and Conference Call

The Company will host a webcast and conference call on Monday, May 8, 2023 at 5:00 p.m. Eastern Time to discuss the Company’s results for the first quarter ended March 31, 2023.

The conference call will be available on the Company’s website at https://ir.guildmortgage.com/. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. The conference call can also be accessed by the following dial-in information:

  • 1-877-300-8521 (Domestic)

  • 1-412-317-6026 (International)

A replay of the call will be available on the Company’s website at https://ir.guildmortgage.com/ approximately two hours after the live call through May 22, 2023. The replay is also available by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (international). The replay pin number is 10176707.

About Guild Holdings Company

Founded in 1960 when the modern U.S. mortgage industry was just forming, Guild Holdings Company is a nationally recognized independent mortgage lender providing residential mortgage products and local in-house origination and servicing. Guild’s collaborative culture and commitment to diversity and inclusion enable it to deliver a personalized experience for each customer. With more than 4,000 employees and over 270 retail branches, Guild has relationships with credit unions, community banks, and other financial institutions and services loans in 49 states and the District of Columbia. Guild’s highly trained loan professionals are experienced in government-sponsored programs such as FHA, VA, USDA, down payment assistance programs and other specialized loan programs. Its shares of Class A common stock trade on the New York Stock Exchange under the symbol GHLD.

Forward-Looking Statements

This press release contains forward-looking statements, including statements about the Company’s expectations for gaining market share, ability to capitalize on M&A opportunities, expectations for increased home sales and mortgage activity, and ability to continue to repurchase shares of the Company’s Class A common stock pursuant to its share repurchase program. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

Important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements include, but are not limited to, the following: any disruptions in the secondary home loan market and their effects on our ability to sell the loans that we originate; any changes in macroeconomic and U.S. residential real estate market conditions; any changes in certain U.S. government-sponsored entities and government agencies, and any organizational or pricing changes in these entities, their guidelines or their current roles; any changes in prevailing interest rates or U.S. monetary policies; the effects of any termination of our servicing rights; the effects of our existing and future indebtedness on our liquidity and our ability to operate our business; any disruption in the technology that supports our origination and servicing platform; our failure to identify, develop and integrate acquisitions of other companies or technologies; the effects of the ongoing COVID-19 pandemic; pressure from existing and new competitors; any failure to maintain or grow our historical referral relationships with our referral partners; any delays in recovering service advances; inaccuracies in the estimates of the fair value of the substantial portion of our assets that are measured on that basis (including our MSRs); any failure to adapt to and implement technological changes; the failure of the internal models that we use to manage risk and make business decisions to produce reliable or accurate results; the degree of business and financial risk associated with certain of our loans; any cybersecurity breaches or other vulnerability involving our computer systems or those of certain of our third-party service providers; our inability to secure additional capital, if needed, to operate and grow our business; the impact of operational risks, including employee or consumer fraud, the obligation to repurchase sold loans in the event of a documentation error, and data processing system failures and errors; any repurchase or indemnification obligations caused by the failure of the loans that we originate to meet certain criteria or characteristics; the seasonality of the mortgage origination industry; any failure to protect our brand and reputation; any non-compliance with the complex laws and regulations governing our mortgage loan origination and servicing activities; material changes to the laws, regulations or practices applicable to reverse mortgage programs; our control by, and any conflicts of interest with, McCarthy Capital Mortgage Investors, LLC; the risks related to our status as a “controlled company”; the significant influence on our business that members of our board and management team are able to exercise as stockholders; our dependence, as a holding company, upon distributions from Guild Mortgage Company LLC to meet our obligations; the risks related to the trading market of our Class A common stock due to our dual class common stock structure; our ability to complete repurchases under the share repurchase program in the amount authorized or at all and the impact of the share repurchase program on our business and financial condition; the identification of material weaknesses in our internal control over financial reporting; and the other risks, uncertainties and factors set forth under Item IA. – Risk Factors and all other disclosures appearing in Guild’s Annual Report on Form 10-K for the year ended December 31, 2022, as well as other documents Guild files from time to time with the Securities and Exchange Commission.

The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release. If one or more events related to these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements.

Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we undertake no obligation to update any forward-looking statement made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments we may make.

Non-GAAP Financial Measures

To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we disclose certain financial measures for our consolidated and operating segment results on both a GAAP and a non-GAAP (adjusted) basis. The non-GAAP financial measures disclosed should be viewed in addition to, and not as an alternative to, results prepared in accordance with GAAP. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies.

Adjusted Net Income (Loss). We define Adjusted Net Income (Loss) as earnings attributable to Guild before the change in the fair value measurements related to our MSRs, contingent liabilities related to completed acquisitions due to changes in valuation assumptions, amortization of acquired intangible assets and stock-based compensation. We exclude these items because we believe they are non-cash expenses that are not reflective of our core operations or indicative of our ongoing operations. Adjusted Net Income (Loss) is also adjusted by applying an estimated effective tax rate to these adjustments. In addition we exclude the change in the fair value of MSRs due to changes in model inputs and assumptions from Adjusted Net Income (Loss) and Adjusted EBITDA below because we believe this non-cash, non-realized adjustment to net revenues is not indicative of our operating performance or results of operations but rather reflects changes in model inputs and assumptions (e.g., prepayment speed, discount rate and cost to service assumptions) that impact the carrying value of our MSRs from period to period.

Adjusted Earnings Per Share. We define Adjusted Earnings Per Share as our adjusted net income divided by the basic weighted average shares outstanding of our Class A and Class B common stock.

Adjusted EBITDA. We define Adjusted EBITDA as earnings before interest (without adjustment for net warehouse interest related to loan fundings and payoff interest related to loan prepayments), taxes, depreciation and amortization and net income attributable to the non-controlling interest exclusive of any change in the fair value measurements of the MSRs due to valuation assumptions, contingent liabilities from business acquisitions and stock-based compensation. We exclude these items because we believe they are non-cash expenses that are not reflective of our core operations or indicative of our ongoing operations.

Adjusted Return on Equity. We define Adjusted Return on Equity as annualized Adjusted Net Income as a percentage of average beginning and ending stockholders’ equity during the period.

We use these non-GAAP financial measures to evaluate our operating performance, to establish budgets and to develop operational goals for managing our business. These non-GAAP financial measures are designed to evaluate operating results exclusive of fair value adjustments that are not indicative of management’s operating performance. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects.

Our non-GAAP financial measures are not prepared in accordance with GAAP and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures rather than net income (loss), which is the most directly comparable financial measure calculated and presented in accordance with GAAP for Adjusted Net Income and Adjusted EBITDA, and Return on Equity, which is the most directly comparable financial measure calculated and presented in accordance with GAAP for Adjusted Return on Equity. These limitations include that these non-GAAP financial measures are not based on a comprehensive set of accounting rules or principles and many of the adjustments to the GAAP financial measures reflect the exclusion of items that are recurring and may be reflected in our financial results for the foreseeable future. In addition, other companies may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison.

For more information on these non-GAAP financial measures, please see the “GAAP to Non-GAAP Reconciliations” included at the end of this release.

Condensed Consolidated Balance Sheets (unaudited)

 

(in thousands, except share and per share amounts)

March 31,

2023

 

December 31,

2022

Assets

 

 

 

Cash and cash equivalents

$

147,783

 

$

137,891

Restricted cash

 

6,237

 

 

8,863

Mortgage loans held for sale

 

858,314

 

 

845,775

Ginnie Mae loans subject to repurchase right

 

591,993

 

 

650,179

Accounts, notes and interest receivable

 

62,166

 

 

58,304

Derivative assets

 

12,206

 

 

3,120

Mortgage servicing rights, net

 

1,112,161

 

 

1,139,539

Intangible assets, net

 

31,088

 

 

33,075

Goodwill

 

182,150

 

 

176,769

Other assets

 

177,422

 

 

186,076

Total assets

$

3,181,520

 

$

3,239,591

Liabilities and stockholders’ equity

 

 

 

Warehouse lines of credit

$

762,062

 

$

713,151

Notes payable

 

130,000

 

 

126,250

Ginnie Mae loans subject to repurchase right

 

592,234

 

 

650,179

Accounts payable and accrued expenses

 

36,579

 

 

34,095

Accrued compensation and benefits

 

25,913

 

 

29,597

Investor reserves

 

16,671

 

 

16,094

Contingent liabilities due to acquisitions

 

2,218

 

 

526

Derivative liabilities

 

8,206

 

 

5,173

Operating lease liabilities

 

81,897

 

 

85,977

Note due to related party

 

 

 

530

Deferred compensation plan

 

92,697

 

 

95,769

Deferred tax liabilities

 

219,764

 

 

232,963

Total liabilities

 

1,968,241

 

 

1,990,304

Commitments and contingencies

 

 

 

Stockholders’ equity

 

 

 

Preferred stock, $0.01 par value; 50,000,000 shares authorized; no shares issued and outstanding

 

 

 

Class A common stock, $0.01 par value; 250,000,000 shares authorized; 20,533,160 and 20,583,130 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 

205

 

 

206

Class B common stock, $0.01 par value; 100,000,000 shares authorized; 40,333,019 shares issued and outstanding at March 31, 2023 and December 31, 2022

 

403

 

 

403

Additional paid-in capital

 

43,915

 

 

42,727

Retained earnings

 

1,168,695

 

 

1,205,885

Non-controlling interest

 

61

 

 

66

Total stockholders’ equity

 

1,213,279

 

 

1,249,287

Total liabilities and stockholders’ equity

$

3,181,520

 

$

3,239,591

Condensed Consolidated Statements of Income (unaudited)

 

 

Three Months Ended

(in thousands, except per share amounts)

Mar 31,

2023

 

Dec 31,

2022

Revenue

 

 

 

Loan origination fees and gain on sale of loans, net

$

92,651

 

 

$

98,445

 

Loan servicing and other fees

 

60,087

 

 

 

57,984

 

Valuation adjustment of mortgage servicing rights

 

(54,871

)

 

 

(29,888

)

Interest income

 

18,245

 

 

 

20,483

 

Interest expense

 

(12,262

)

 

 

(12,829

)

Other income, net

 

35

 

 

 

107

 

Net revenue

 

103,885

 

 

 

134,302

 

Expenses

 

 

 

Salaries, incentive compensation and benefits

 

111,120

 

 

 

116,292

 

General and administrative

 

20,883

 

 

 

17,932

 

Occupancy, equipment and communication

 

17,430

 

 

 

17,120

 

Depreciation and amortization

 

3,738

 

 

 

3,909

 

Provision for foreclosure losses

 

1,514

 

 

 

2,274

 

Total expenses

 

154,685

 

 

 

157,527

 

Loss before income tax benefit

 

(50,800

)

 

 

(23,225

)

Income tax benefit

 

(13,605

)

 

 

(8,226

)

Net loss

 

(37,195

)

 

 

(14,999

)

Net (loss) income attributable to non-controlling interest

 

(5

)

 

 

7

 

Net loss attributable to Guild

$

(37,190

)

 

$

(15,006

)

 

 

 

 

Net loss per share attributable to Class A and Class B Common Stock:

 

 

 

Basic

$

(0.61

)

 

$

(0.25

)

Diluted

$

(0.61

)

 

$

(0.25

)

Weighted average shares outstanding of Class A and Class B Common Stock:

 

 

 

Basic

 

60,900

 

 

 

60,914

 

Diluted

 

60,900

 

 

 

60,914

 

Key Performance Indicators

Management reviews several key performance indicators to evaluate our business results, measure our performance and identify trends to inform our business decisions. Summary data for these key performance indicators is listed below.

 

Three Months Ended

($ and units in thousands)

Mar 31, 2023

 

Dec 31, 2022

Origination Data

 

 

 

$ Total in-house origination(1)

$

2,701,426

 

$

2,975,912

# Total in-house origination

 

9

 

 

9

$ Retail in-house origination

$

2,558,801

 

$

2,855,174

# Retail in-house origination

 

8

 

 

9

$ Retail brokered origination(2)

$

41,704

 

$

35,435

Total originations

$

2,743,130

 

$

3,011,347

Gain on sale margin (bps)(3)

 

343

 

 

331

Pull-through adjusted locked volume(4)

$

3,258,998

 

$

2,804,503

Gain on sale margin on pull-through adjusted locked volume (bps)(5)

 

284

 

 

351

Purchase recapture rate(6)

 

24%

 

 

25%

Refinance recapture rate(7)

 

30%

 

 

20%

Purchase origination %

 

92%

 

 

93%

Servicing Data

 

 

 

UPB (period end)

$

79,916,577

 

$

78,892,987

_________________

(1)

Includes retail and correspondent loans and excludes brokered loans.

(2)

Brokered loans are defined as loans we originate in the retail channel that are processed by us but underwritten and closed by another lender. These loans are typically for products we choose not to offer in-house.

(3)

Represents loan origination fees and gain on sale of loans, net divided by total in-house origination to derive basis points.

(4)

Pull-through adjusted locked volume is equal to total locked volume multiplied by pull-through rates of 84.0% and 93.4% as of March 31, 2023 and December 31, 2022, respectively. We estimate the pull-through rate based on changes in pricing and actual borrower behavior using a historical analysis of loan closing data and “fallout” data with respect to the number of commitments that have historically remained unexercised. The decrease from the prior quarter is primarily due to reassessing our assumptions within the valuation model and is not indicative of a change in our operations.

(5)

Represents loan origination fees and gain on sale of loans, net divided by pull-through adjusted locked volume.

(6)

Purchase recapture rate is calculated as the ratio of (i) UPB of our clients that originated a new mortgage with us for the purchase of a home in a given period, to (ii) total UPB of our clients that paid off their existing mortgage as a result of selling their home in a given period.

(7)

Refinance recapture rate is calculated as the ratio of (i) UPB of our clients that originated a new mortgage loan for the purpose of refinancing an existing mortgage with us in a given period, to (ii) total UPB of our clients that paid off their existing mortgage as a result of refinancing their home in the same period

GAAP to Non-GAAP Reconciliations

Reconciliation of Net Loss to Adjusted Net Loss (unaudited)

 

 

Three Months Ended

(in millions, except per share amounts)

Mar 31,

2023

 

Dec 31,

2022

Net loss

$

(37.2

)

 

$

(15.0

)

Net (loss) income attributable to non-controlling interest(1)

 

 

 

 

 

Net loss attributable to Guild

$

(37.2

)

 

$

(15.0

)

Add adjustments:

 

 

 

Change in fair value of MSRs due to model inputs and assumption

 

43.7

 

 

 

16.9

 

Change in fair value of contingent liabilities due to acquisitions

 

 

 

 

 

Amortization of acquired intangible assets

 

2.0

 

 

 

2.0

 

Stock-based compensation

 

1.8

 

 

 

2.4

 

Tax impact of adjustments(2)

 

(12.7

)

 

 

(6.4

)

Adjusted Net Loss

$

(2.5

)

 

$

(0.1

)

 

 

 

 

Weighted average shares outstanding of Class A and Class B Common Stock

 

61

 

 

 

61

 

Loss per share

$

(0.61

)

 

$

(0.25

)

Adjusted loss per share

$

(0.04

)

 

$

 

_________________
Amounts may not foot due to rounding

(1)

Net (loss) income attributable to non-controlling interest was $(5) thousand and $7 thousand for the three months ended March 31, 2023 and December 31, 2022, respectively.

(2)

Estimated effective tax rate used was 26.8% and 35.4% for the three months ended March 31, 2023 and December 31, 2022, respectively.

Reconciliation of Net Loss to Adjusted EBITDA

(unaudited)

 

 

Three Months Ended

(in millions)

Mar 31,

2023

 

Dec 31,

2022

Net loss

$

(37.2

)

 

$

(15.0

)

Add adjustments:

 

 

 

Interest expense on non-funding debt

 

2.8

 

 

 

2.0

 

Income tax benefit

 

(13.6

)

 

 

(8.2

)

Depreciation and amortization

 

3.7

 

 

 

3.9

 

Change in fair value of MSRs due to model inputs and assumptions

 

43.7

 

 

 

16.9

 

Change in fair value of contingent liabilities due to acquisitions

 

 

 

 

 

Stock-based compensation

 

1.8

 

 

 

2.4

 

Adjusted EBITDA

$

1.1

 

 

$

1.9

 

Reconciliation of Return on Equity to Adjusted Return on Equity

(unaudited)

 

 

Three Months Ended

($ in millions)

Mar 31,

2023

 

Dec 31,

2022

Income Statement Data:

 

 

 

Net loss attributable to Guild

$

(37.2

)

 

$

(15.0

)

Adjusted net loss

$

(2.5

)

 

$

(0.1

)

 

 

 

 

Average stockholders’ equity

$

1,231.3

 

 

$

1,257.4

 

Return on Equity

 

(12.1

)%

 

 

(4.8

)%

Adjusted Return on Equity

 

(0.8

)%

 

 

%

 

Investors:

[email protected]

858-956-5130

Media:

Melissa Rue

Nuffer, Smith, Tucker

[email protected]

619-296-0605 Ext. 247

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Finance Banking Professional Services Residential Building & Real Estate Construction & Property

MEDIA:

Permian Resources Announces First Quarter 2023 Results

Permian Resources Announces First Quarter 2023 Results

MIDLAND, Texas–(BUSINESS WIRE)–
Permian Resources Corporation (“Permian Resources” or the “Company”) (NYSE: PR) today announced its first quarter 2023 financial and operational results.

First Quarter Financial and Operational Highlights

  • Delivered total production of 153.8 MBoe/d, ahead of guidance, and oil production of 78.3 MBbls/d, in-line with guidance

  • Announced total accrued capital expenditures of $360 million and total cash capital expenditures of $315 million

  • Reported net cash provided by operating activities of $438 million and adjusted free cash flow1 of $101 million (accrued capital expenditures) or $146 million (cash capital expenditures)

  • Delivered total return of capital of $85 million through the base and variable dividends and stock repurchases:

    • Announced quarterly base dividend of $0.05 per share

    • Initiated inaugural variable dividend of $0.05 per share

    • Repurchased $29.4 million of Class C Common Stock

  • Closed the previously announced bolt-on acquisition in Lea County and midstream infrastructure divestiture in Reeves County

Management Commentary

“Permian Resources delivered another strong operational quarter as we remain focused on executing on our 2023 plan, with quarterly production and costs in-line with or ahead of expectations,” said Will Hickey, Co-CEO of Permian Resources. “We continue to build upon our operational track record and are committed to driving strong well results, improving operational efficiencies and maintaining capital discipline.”

“In the inaugural quarter of our variable return program, we are pleased to be able to return $85 million to shareholders through the base dividend, variable dividend and share buybacks,” said James Walter, Co-CEO of the Company. “Going forward, we will continue to leverage our high-quality assets, efficient operations and strong financial position to provide a unique and attractive value proposition to investors.”

Operational and Financial Results

Permian Resources met or exceeded its first quarter production targets while continuing to drive cost efficiency improvements and remains on track to achieve its full year production and capital expenditure guidance. During the quarter, average daily crude oil production was 78,332 barrels of oil per day (“Bbls/d”), and first quarter total production averaged 153,822 barrels of oil equivalent per day (“Boe/d”).

First quarter average realized prices were $74.38 per barrel of oil, $1.81 per Mcf of natural gas and $27.12 per barrel of natural gas liquids (“NGLs”), excluding the effects of hedges and GP&T expenses. Oil (98% of NYMEX oil) and NGL (36% of NYMEX oil) realizations were in-line with Company expectations. Realized natural gas prices were lower than expected, which was primarily driven by regional pricing dynamics that the Company believes to be non-recurring in nature. Permian Resources expects continued weakness for Waha natural gas prices during parts of the year and has reduced its exposure through the use of Waha basis hedges, in addition to pricing a portion of its residue natural gas at Houston Ship Channel.

First quarter total controllable cash costs (LOE, cash G&A and GP&T) were $7.86 per Boe, which were in-line with expectations. The Company anticipates total controllable cash costs on a per unit basis to decline during the year as total production is expected to grow. Total accrued capital expenditures were $360 million during the first quarter, and total cash capital expenditures realized for the quarter were $315 million. The difference between accrued and cash capital expenditures during the quarter was driven by normal course changes in working capital, and the Company expects accrued and cash capital expenditures to be approximately equivalent over time.

For the quarter, Permian Resources generated net cash provided by operating activities of $438 million and adjusted free cash flow1 of $101 million, utilizing accrued capital expenditures, or $146 million, utilizing cash capital expenditures. The Company also reported net income attributable to Class A Common Stock during the first quarter of $102 million, or $0.35 per basic share. First quarter adjusted net income1 was $192 million or $0.34 per adjusted basic share.

Since its last update on February 22, 2023, the Company has added incremental oil hedges for the second half of 2023 and full year 2024 and 2025. For the second half of 2023, the Company entered into 3,000 Bbls/d of incremental oil swaps at a weighted average fixed price of $77.32 per barrel. As a result, Permian Resources now has approximately 30% of its expected crude oil production hedged for the remainder of 2023 (using the mid-point of guidance) at a weighted average floor price of $82.48 per Bbl. For the full year 2024, Permian Resources has 17,000 Bbls/d of oil hedged at a weighted average fixed price of $75.48 per Bbl. The Company has 5,000 Bbls/d of oil hedged in 2025 at a weighted average fixed price of $68.00 per Bbl.

In addition to the hedge positions discussed above, the Company has certain other natural gas hedges, crude oil and natural gas basis swaps and crude oil roll differential swaps in place. (For a summary table of Permian Resources’ derivative contracts as of April 30, 2023, please see the Appendix to this press release.)

Permian Resources continues to maintain a strong financial position and low leverage profile. In April, the Company’s bank group reaffirmed the borrowing base under its revolving credit facility at $2.5 billion and maintained its level of elected commitments at $1.5 billion. At March 31, 2023, the Company had $26 million in cash on hand and $285 million in borrowings outstanding under the facility. Total liquidity was approximately $1.2 billion, including letters of credit. Net debt-to-LQA EBITDAX1 at March 31, 2023 was approximately 1.0x, and the Company has no debt maturities until 2026.

Shareholder Returns

Permian Resources announced today that its Board of Directors (the “Board”) declared a quarterly base cash dividend of $0.05 per share of Class A common stock, or $0.20 per share on an annualized basis. Additionally, based upon first quarter financial results, the Board has declared a quarterly variable cash dividend of $0.05 per share of Class A common stock. Combined, the base and variable dividends represent a total of $0.10 per share. The base and variable dividends are payable on May 24, 2023 to shareholders of record as of May 16, 2023.

Permian Resources returned additional capital to shareholders in the first quarter by repurchasing 2.75 million shares of Class C Common Stock for $29.4 million during a secondary offering from selling shareholders.

Portfolio Optimization Review

During the first quarter, Permian Resources closed a series of portfolio management transactions, which consisted of a bolt-on acquisition, a sizable acreage swap and a divestiture of a portion of its water infrastructure, in addition to properties added through its ongoing grassroots acquisition program.

Permian Resources closed the previously announced transaction to acquire 4,000 net leasehold acres, 3,300 net royalty acres and associated production, located predominantly in Lea County, New Mexico for a purchase price of $98 million, before post-closing adjustments. The acquired operated position consists of largely undeveloped acreage and is contiguous to one of the Company’s existing core blocks in Lea County.

Also during the quarter, the Company executed an acreage trade that further bolstered its position in Eddy County, New Mexico. Permian Resources traded into approximately 3,400 net acres, consisting of seven newly created, operated drilling spacing units (DSUs) adjacent to its current position and increased working interest in existing acreage on the Company’s near-term drilling schedule. As part of the transaction, the Company traded out of approximately 3,200 net acres of lower working interest acreage, which was not on its near-term drill schedule and had no material production.

“We are excited to trade into high quality inventory in one of our core operating areas, which has demonstrated highly productive results. Importantly, we expect to begin drilling activity on approximately half of the inbound acreage over the next twelve months, making this type of transaction highly accretive to shareholders,” said James Walter, Co-CEO. “We believe active portfolio management is a key competency for Permian Resources and will continue to drive value for our shareholders.”

Finally, as previously announced, the Company divested a portion of its saltwater disposal wells and associated produced water infrastructure in Reeves County, Texas for total cash consideration of $125 million received at closing, with $60 million of such consideration subject to future performance obligations by the Company.

Quarterly Report on Form 10-Q

Permian Resources’ financial statements and related footnotes will be available in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which is expected to be filed with the Securities and Exchange Commission (“SEC”) on May 9, 2023.

Conference Call and Webcast

Permian Resources will host an investor conference call on Tuesday, May 9, 2023 at 9:00 a.m. Central (10:00 a.m. Eastern) to discuss first quarter operating and financial results. Interested parties may join the webcast by visiting Permian Resources’ website at www.permianres.com and clicking on the webcast link or by dialing (888) 396-8049 (Conference ID: 92425142) at least 15 minutes prior to the start of the call. A replay of the call will be available on the Company’s website or by phone at (877) 674-7070 (Access Code: 425142) for a 14-day period following the call.

About Permian Resources

Headquartered in Midland, Texas, Permian Resources is an independent oil and natural gas company focused on the responsible acquisition, optimization and development of high-return oil and natural gas properties. The Company’s assets and operations are located in the core of the Delaware Basin. For more information, please visit www.permianres.com.

Cautionary Note Regarding Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this press release, the words “could,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “goal,” “plan,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events.

Forward-looking statements may include statements about:

  • volatility of oil, natural gas and NGL prices or a prolonged period of low oil, natural gas or NGL prices and the effects of actions by, or disputes among or between, members of the Organization of Petroleum Exporting Countries (“OPEC”), such as Saudi Arabia, and other oil and natural gas producing countries, such as Russia, with respect to production levels or other matters related to the price of oil;

  • the effects of excess supply of oil and natural gas resulting from reduced demand caused by the COVID-19 pandemic and the actions taken in response by certain oil and natural gas producing countries;

  • political and economic conditions in or affecting other producing regions or countries, including the Middle East, Russia, Eastern Europe, Africa and South America;

  • our ability to realize the anticipated benefits and synergies from the recently-closed merger and effectively integrate the assets of Centennial and Colgate;

  • our business strategy and future drilling plans;

  • our reserves and our ability to replace the reserves we produce through drilling and property acquisitions;

  • our drilling prospects, inventories, projects and programs;

  • our financial strategy, return of capital program, liquidity and capital required for our development program;

  • our realized oil, natural gas and NGL prices;

  • the timing and amount of our future production of oil, natural gas and NGLs;

  • our ability to identify, complete and effectively integrate acquisitions of properties or businesses;

  • our hedging strategy and results;

  • our competition and government regulations;

  • our ability to obtain permits and governmental approvals;

  • our pending legal or environmental matters;

  • the marketing and transportation of our oil, natural gas and NGLs;

  • our leasehold or business acquisitions;

  • costs of developing or operating our properties;

  • our anticipated rate of return;

  • general economic conditions;

  • weather conditions in the areas where we operate;

  • credit markets;

  • uncertainty regarding our future operating results;

  • our plans, objectives, expectations and intentions contained in this press release that are not historical; and

  • the other factors described in our most recent Annual Report on Form 10-K, and any updates to those factors set forth in our subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

We caution you that these forward-looking statements are subject to all of the risks and uncertainties, most of which are difficult to predict and many of which are beyond our control, incident to the development, production, gathering and sale of oil and natural gas. These risks include, but are not limited to, commodity price volatility, inflation, lack of availability of drilling and production equipment and services, risks relating to the merger, environmental risks, drilling and other operating risks, regulatory changes, the uncertainty inherent in estimating oil and gas reserves and in projecting future rates of production, cash flow and access to capital, the timing of development expenditures and the other risks described in our filings with the SEC.

Reserve engineering is a process of estimating underground accumulations of oil and natural gas that cannot be measured in an exact way. The accuracy of any oil and gas reserve estimate depends on the quality of available data, the interpretation of such data, and price and cost assumptions made by reserve engineers. In addition, the results of drilling, testing and production activities may justify revisions of estimates that were made previously. If significant, such revisions would change the schedule of any further production and development drilling. Accordingly, reserve estimates may differ significantly from the quantities of oil and natural gas that are ultimately recovered.

Should one or more of the risks or uncertainties described in this press release occur, or should underlying assumptions prove incorrect, our actual results and plans could differ materially from those expressed in any forward-looking statements. All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by this cautionary statement. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.

Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

1) Adjusted Net Income, Adjusted Free Cash Flow and Net Debt-to-LQA EBITDAX are non-GAAP financial measures. See “Non-GAAP Financial Measures” included within the Appendix of this press release for related disclosures and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP.

Permian Resources Corporation

Operating Highlights

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Net revenues (in thousands):

 

 

 

Oil sales

$

524,386

 

 

$

262,767

 

Natural gas sales(1)

 

32,122

 

 

 

39,018

 

NGL sales(2)

 

59,760

 

 

 

45,492

 

Oil and gas sales

$

616,268

 

 

$

347,277

 

 

 

 

 

Average sales prices:

 

 

 

Oil (per Bbl)

$

74.38

 

 

$

89.17

 

Effect of derivative settlements on average price (per Bbl)

 

3.65

 

 

 

(12.82

)

Oil including the effects of hedging (per Bbl)

$

78.03

 

 

$

76.35

 

 

 

 

 

Average NYMEX price for oil (per Bbl)

$

76.13

 

 

$

94.40

 

Oil differential from NYMEX

 

(1.75

)

 

 

(5.23

)

 

 

 

 

Natural gas price excluding the effects of GP&T (per Mcf)(1)

$

1.81

 

 

$

3.93

 

 

 

 

 

Effect of derivative settlements on average price (per Mcf)

 

0.58

 

 

 

(0.51

)

Natural gas including the effects of hedging (per Mcf)

$

2.39

 

 

$

3.42

 

 

 

 

 

Average NYMEX price for natural gas (per MMBtu)

$

2.67

 

 

$

4.60

 

Natural gas differential from NYMEX

 

(0.86

)

 

 

(0.67

)

 

 

 

 

NGL price excluding the effects of GP&T (per Bbl)(2)

$

27.12

 

 

$

49.37

 

 

 

 

 

Net production:

 

 

 

Oil (MBbls)

 

7,050

 

 

 

2,947

 

Natural gas (MMcf)

 

23,974

 

 

 

9,925

 

NGL (MBbls)

 

2,798

 

 

 

921

 

Total (MBoe)(3)

 

13,844

 

 

 

5,522

 

 

 

 

 

Average daily net production:

 

 

 

Oil (Bbls/d)

 

78,332

 

 

 

32,741

 

Natural gas (Mcf/d)

 

266,374

 

 

 

110,280

 

NGL (Bbls/d)

 

31,094

 

 

 

10,238

 

Total (Boe/d)(3)

 

153,822

 

 

 

61,359

 

_______________________

(1)

Natural gas sales include a portion of gathering, processing and transportation expenses (“GP&T”), that are reflected as a reduction to natural gas sales of $11.3 million for the three months ended March 31, 2023 and none for the three months ended March 31, 2022. Natural gas average sales price excludes $0.47 per Mcf of these GP&T charges for the three months ended March 31, 2023.

(2)

NGL sales include a portion of GP&T, that are reflected as a reduction to NGL sales of $16.1 million for the three months ended March 31, 2023 and none for the three months ended March 31, 2022. NGL average sales prices excludes $5.77 per Bbl of these GP&T charges for the three months ended March 31, 2023.

(3)

Calculated by converting natural gas to oil equivalent barrels at a ratio of six Mcf of natural gas to one Boe.

Permian Resources Corporation

Operating Expenses

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Operating costs (in thousands):

 

 

 

Lease operating expenses

$

74,532

 

 

$

28,734

 

Severance and ad valorem taxes

 

48,509

 

 

 

25,051

 

Gathering, processing and transportation expenses

 

15,482

 

 

 

21,891

 

Operating cost metrics:

 

 

 

Lease operating expenses (per Boe)

$

5.38

 

 

$

5.20

 

Severance and ad valorem taxes (% of revenue)

 

7.9

%

 

 

7.2

%

Gathering, processing and transportation expenses (per Boe)

$

1.12

 

 

$

3.96

 

Permian Resources Corporation

Consolidated Statements of Operations (unaudited)

(in thousands, except per share data)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Operating revenues

 

 

 

Oil and gas sales

$

616,268

 

 

$

347,277

 

Operating expenses

 

 

 

Lease operating expenses

 

74,532

 

 

 

28,734

 

Severance and ad valorem taxes

 

48,509

 

 

 

25,051

 

Gathering, processing and transportation expenses

 

15,482

 

 

 

21,891

 

Depreciation, depletion and amortization

 

188,219

 

 

 

71,009

 

General and administrative expenses

 

35,474

 

 

 

30,603

 

Merger and integration expense

 

13,299

 

 

 

 

Impairment and abandonment expense

 

245

 

 

 

2,627

 

Exploration and other expenses

 

4,374

 

 

 

2,307

 

Total operating expenses

 

380,134

 

 

 

182,222

 

Net gain (loss) on sale of long-lived assets

 

66

 

 

 

82

 

Income (loss) from operations

 

236,200

 

 

 

165,137

 

 

 

 

 

Other income (expense)

 

 

 

Interest expense

 

(36,777

)

 

 

(13,154

)

Net gain (loss) on derivative instruments

 

54,512

 

 

 

(129,523

)

Other income (expense)

 

120

 

 

 

118

 

Total other income (expense)

 

17,855

 

 

 

(142,559

)

 

 

 

 

Income (loss) before income taxes

 

254,055

 

 

 

22,578

 

Income tax (expense) benefit

 

(34,254

)

 

 

(6,776

)

Net income (loss)

 

219,801

 

 

 

15,802

 

Less: Net (income) loss attributable to noncontrolling interest

 

(117,681

)

 

 

 

Net income (loss) attributable to Class A Common Stock

$

102,120

 

 

$

15,802

 

 

 

 

 

Income (loss) per share of Class A Common Stock:

 

 

 

Basic

$

0.35

 

 

$

0.06

 

Diluted

$

0.31

 

 

$

0.05

 

 

 

 

 

Weighted average Class A Common Stock outstanding:

 

 

 

Basic

 

295,913

 

 

 

284,851

 

Diluted

 

335,848

 

 

 

319,680

 

Permian Resources Corporation

Consolidated Balance Sheets (unaudited)

(in thousands, except share and per share amounts)

 

 

March 31, 2023

 

December 31, 2022

ASSETS

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

25,593

 

 

$

59,545

 

Accounts receivable, net

 

301,581

 

 

 

282,846

 

Derivative instruments

 

108,293

 

 

 

100,797

 

Prepaid and other current assets

 

8,528

 

 

 

20,602

 

Total current assets

 

443,995

 

 

 

463,790

 

Property and Equipment

 

 

 

Oil and natural gas properties, successful efforts method

 

 

 

Unproved properties

 

1,433,639

 

 

 

1,424,744

 

Proved properties

 

9,283,311

 

 

 

8,869,174

 

Accumulated depreciation, depletion and amortization

 

(2,600,676

)

 

 

(2,419,692

)

Total oil and natural gas properties, net

 

8,116,274

 

 

 

7,874,226

 

Other property and equipment, net

 

16,294

 

 

 

15,173

 

Total property and equipment, net

 

8,132,568

 

 

 

7,889,399

 

Noncurrent assets

 

 

 

Operating lease right-of-use assets

 

70,289

 

 

 

64,792

 

Other noncurrent assets

 

76,306

 

 

 

74,611

 

TOTAL ASSETS

$

8,723,158

 

 

$

8,492,592

 

LIABILITIES AND EQUITY

 

 

 

Current liabilities

 

 

 

Accounts payable and accrued expenses

$

619,828

 

 

$

562,156

 

Operating lease liabilities

 

34,959

 

 

 

29,759

 

Derivative instruments

 

344

 

 

 

1,998

 

Other current liabilities

 

26,867

 

 

 

11,656

 

Total current liabilities

 

681,998

 

 

 

605,569

 

Noncurrent liabilities

 

 

 

Long-term debt, net

 

2,042,916

 

 

 

2,140,798

 

Asset retirement obligations

 

46,613

 

 

 

40,947

 

Deferred income taxes

 

50,414

 

 

 

4,430

 

Operating lease liabilities

 

41,570

 

 

 

41,341

 

Other noncurrent liabilities

 

50,961

 

 

 

3,211

 

Total liabilities

 

2,914,472

 

 

 

2,836,296

 

Commitments and contingencies (Note 12)

 

 

 

Shareholders’ equity

 

 

 

Common stock, $0.0001 par value, 1,500,000,000 shares authorized:

 

 

 

Class A: 321,723,961 shares issued and 313,958,894 shares outstanding at March 31, 2023 and 298,640,260 shares issued and 288,532,257 shares outstanding at December 31, 2022

 

32

 

 

 

30

 

Class C: 245,644,075 shares issued and outstanding at March 31, 2023 and 269,300,000 shares issued and outstanding at December 31, 2022

 

25

 

 

 

27

 

Additional paid-in capital

 

2,891,528

 

 

 

2,698,465

 

Retained earnings (accumulated deficit)

 

323,677

 

 

 

237,226

 

Total shareholders’ equity

 

3,215,262

 

 

 

2,935,748

 

Noncontrolling interest

 

2,593,424

 

 

 

2,720,548

 

Total equity

 

5,808,686

 

 

 

5,656,296

 

TOTAL LIABILITIES AND EQUITY

$

8,723,158

 

 

$

8,492,592

 

Permian Resources Corporation

Consolidated Statements of Cash Flows (unaudited)

(in thousands)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Cash flows from operating activities:

 

 

 

Net income (loss)

$

219,801

 

 

$

15,802

 

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

Depreciation, depletion and amortization

 

188,219

 

 

 

71,009

 

Stock-based compensation expense – equity awards

 

17,871

 

 

 

5,545

 

Stock-based compensation expense – liability awards

 

 

 

 

13,720

 

Impairment and abandonment expense

 

245

 

 

 

2,627

 

Deferred tax expense (benefit)

 

33,454

 

 

 

6,776

 

Net (gain) loss on sale of long-lived assets

 

(66

)

 

 

(82

)

Non-cash portion of derivative (gain) loss

 

(14,777

)

 

 

86,645

 

Amortization of debt issuance costs and debt discount

 

2,796

 

 

 

1,492

 

Changes in operating assets and liabilities:

 

 

 

(Increase) decrease in accounts receivable

 

(1,503

)

 

 

(53,824

)

(Increase) decrease in prepaid and other assets

 

(1,016

)

 

 

(415

)

Increase (decrease) in accounts payable and other liabilities

 

(6,811

)

 

 

10,825

 

Net cash provided by operating activities

 

438,213

 

 

 

160,120

 

Cash flows from investing activities:

 

 

 

Acquisition of oil and natural gas properties, net

 

(100,755

)

 

 

(1,928

)

Drilling and development capital expenditures

 

(315,285

)

 

 

(81,156

)

Purchases of other property and equipment

 

(1,204

)

 

 

(1,052

)

Contingent considerations received related to divestiture

 

60,000

 

 

 

 

Proceeds from sales of oil and natural gas properties

 

65,116

 

 

 

48

 

Net cash used in investing activities

 

(292,128

)

 

 

(84,088

)

Cash flows from financing activities:

 

 

 

Proceeds from borrowings under revolving credit facility

 

160,000

 

 

 

135,000

 

Repayment of borrowings under revolving credit facility

 

(260,000

)

 

 

(160,000

)

Debt issuance costs

 

 

 

 

(8,530

)

Proceeds from exercise of stock options

 

231

 

 

 

1

 

Share repurchase

 

(29,418

)

 

 

 

Dividends paid

 

(15,192

)

 

 

 

Distributions paid to noncontrolling interest owners

 

(13,324

)

 

 

 

Class A Common Stock repurchased from employees for taxes due upon share vestings

 

(32,160

)

 

 

(1,259

)

Net cash provided by (used in) financing activities

 

(189,863

)

 

 

(34,788

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

(43,778

)

 

 

41,244

 

Cash, cash equivalents and restricted cash, beginning of period

 

69,932

 

 

 

9,935

 

Cash, cash equivalents and restricted cash, end of period

$

26,154

 

 

$

51,179

 

Reconciliation of cash, cash equivalents and restricted cash presented on the Consolidated Statements of Cash Flows for the periods presented:

 

 

Three Months Ended March 31,

 

 

2023

 

 

2022

Cash and cash equivalents

$

25,593

 

$

50,624

Restricted cash

 

561

 

 

555

Total cash, cash equivalents and restricted cash

$

26,154

 

$

51,179

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with U.S. generally accepted accounting principles (“GAAP”), our earnings release contains non-GAAP financial measures as described below.

Adjusted EBITDAX

Adjusted EBITDAX is a supplemental non-GAAP financial measure that is used by management and external users of our consolidated financial statements, such as industry analysts, investors, lenders and rating agencies. We define Adjusted EBITDAX as net income attributable to Class A Common Stock before net income/loss attributable to noncontrolling interest, interest expense, income taxes, depreciation, depletion and amortization, impairment and abandonment expense, non-cash gains or losses on derivatives, stock-based compensation (not cash-settled), exploration and other expenses, merger and integration expense, gain/loss from the sale of long-lived assets and non-recurring items. Adjusted EBITDAX is not a measure of net income as determined by GAAP.

Our management believes Adjusted EBITDAX is useful as it allows them to more effectively evaluate our operating performance and compare the results of our operations from period to period and against our peers, without regard to our financing methods or capital structure. We exclude the items listed above from net income in arriving at Adjusted EBITDAX because these amounts can vary substantially from company to company within our industry depending upon accounting methods and book values of assets, capital structures and the method by which the assets were acquired. Adjusted EBITDAX should not be considered as an alternative to, or more meaningful than, net income as determined in accordance with GAAP or as an indicator of our operating performance or liquidity. Certain items excluded from Adjusted EBITDAX are significant components in understanding and assessing a company’s financial performance, such as a company’s cost of capital and tax structure, as well as the historic costs of depreciable assets, none of which are components of Adjusted EBITDAX. Our presentation of Adjusted EBITDAX should not be construed as an inference that our results will be unaffected by unusual or nonrecurring items. Our computations of Adjusted EBITDAX may not be comparable to other similarly titled measures of other companies.

The following table presents a reconciliation of Adjusted EBITDAX to net income, which is the most directly comparable financial measure calculated and presented in accordance with GAAP:

 

Three Months Ended

(in thousands)

3/31/2023

 

12/31/2022

 

9/30/2022

 

6/30/2022

 

3/31/2022

Adjusted EBITDAX reconciliation to net income:

 

 

 

 

 

 

 

 

 

Net income (loss) attributable to Class A Common Stock

$

102,120

 

 

$

83,050

 

 

$

224,359

 

 

$

191,826

 

 

$

15,802

 

Net income (loss) attributable to noncontrolling interest

 

117,681

 

 

 

115,658

 

 

 

119,145

 

 

 

 

 

 

 

Interest expense

 

36,777

 

 

 

39,358

 

 

 

28,807

 

 

 

14,326

 

 

 

13,154

 

Income tax expense

 

34,254

 

 

 

40,860

 

 

 

31,169

 

 

 

41,487

 

 

 

6,776

 

Depreciation, depletion and amortization

 

188,219

 

 

 

182,052

 

 

 

109,500

 

 

 

82,117

 

 

 

71,009

 

Impairment and abandonment expense

 

245

 

 

 

244

 

 

 

498

 

 

 

506

 

 

 

2,627

 

Non-cash derivative (gain) loss

 

(14,777

)

 

 

88,635

 

 

 

(213,503

)

 

 

(39,514

)

 

 

86,645

 

Stock-based compensation expense(1)

 

16,707

 

 

 

54,342

 

 

 

18,896

 

 

 

(2,487

)

 

 

18,834

 

Exploration and other expenses

 

4,374

 

 

 

4,765

 

 

 

2,352

 

 

 

1,954

 

 

 

2,307

 

Merger and integration expense

 

13,299

 

 

 

12,469

 

 

 

59,270

 

 

 

5,685

 

 

 

 

(Gain) loss on sale of long-lived assets

 

(66

)

 

 

(13

)

 

 

3

 

 

 

1,406

 

 

 

(82

)

Adjusted EBITDAX

$

498,833

 

 

$

621,420

 

 

$

380,496

 

 

$

297,306

 

 

$

217,072

 

_______________________

(1)

Includes stock-based compensation for equity awards and also for cash-based liability awards that have not yet been settled in cash, both of which relate to general and administrative employees only. Stock-based compensation amounts for geographical and geophysical personnel are included within the Exploration and other expenses line item.

Net Debt-to-LQA EBITDAX

Net debt-to-LQA EBITDAX is a non-GAAP financial measure. We define net debt as long-term debt, net, plus unamortized debt discount and debt issuance costs on our senior notes minus cash and cash equivalents.

We define net debt-to-LQA EBITDAX as net debt (defined above) divided by Adjusted EBITDAX (defined and reconciled in the section above) for the three months ended March 31, 2023, on an annualized basis. We refer to this metric to show trends that investors may find useful in understanding our ability to service our debt. This metric is widely used by professional research analysts, including credit analysts, in the valuation and comparison of companies in the oil and gas exploration and production industry. The following table presents a reconciliation of net debt to long-term debt, net and the calculation of net debt-to-LQA EBITDAX for the period presented:

(in thousands)

March 31, 2023

Long-term debt, net

2,042,916

 

Unamortized debt discount and debt issuance costs on senior notes

57,883

 

Long-term debt

2,100,799

 

Less: cash and cash equivalents

(25,593

)

Net debt (Non-GAAP)

2,075,206

 

LQA EBITDAX(1)

1,995,332

 

Net debt-to-LQA EBITDAX

1.0

 

(1)

Represents adjusted EBITDAX (defined and reconciled in the section above) for the three months ended March 31, 2023, on an annualized basis.

Adjusted Shares

Adjusted basic and diluted weighted average shares outstanding (“Adjusted Basic and Diluted Shares”) are non-GAAP financial measures defined as basic and diluted weighted average shares outstanding adjusted to reflect the weighted average shares of our Class C Common Stock outstanding during the period.

Our Adjusted Basic and Diluted Shares provide a comparable per share measurement when presenting results such as adjusted free cash flow and adjusted net income that include the interests of both net income attributable to Class A Common Stock and the net income attributable to our noncontrolling interest. Adjusted Basic and Diluted Shares are used in calculating several metrics that we use as supplemental financial measurements in the evaluation of our business.

The following table presents a reconciliation of Adjusted Basic and Diluted Shares to basic and diluted weighted average shares outstanding, which are the most directly comparable financial measure calculated and presented in accordance with GAAP:

 

Three Months Ended March 31,

(in thousands)

2023

 

2022

Basic weighted average shares of Class A Common Stock outstanding

295,913

 

284,851

Weighted average shares of Class C Common Stock

263,369

 

Adjusted basic weighted average shares outstanding

559,282

 

284,851

 

 

 

 

Basic weighted average shares of Class A Common Stock outstanding

295,913

 

284,851

Add: Dilutive effects of Convertible Senior Notes

27,314

 

27,074

Add: Dilutive effects of equity awards and ESPP shares

12,621

 

7,755

Diluted weighted average shares of Class A Common Stock outstanding

335,848

 

319,680

Weighted average shares of Class C Common Stock

263,369

 

Adjusted diluted weighted average shares outstanding

599,217

 

319,680

Free Cash Flow and Adjusted Free Cash Flow

Free cash flow and adjusted free cash flow are supplemental non-GAAP financial measures that are used by management and external users of our consolidated financial statements, such as industry analysts, investors, lenders and rating agencies. We define free cash flow as net cash provided by operating activities before changes in working capital, less capital expenditures incurred/paid and adjusted free cash flow as free cash flow before non-recurring merger and integration expense.

Our management believes free cash flow and adjusted free cash flow are useful indicators of the Company’s ability to internally fund its exploration and development activities, to service its existing level of indebtedness or incur additional debt, without regard to the timing of settlement of either operating assets and liabilities or accounts payable related to capital expenditures. The Company believes that these measures, as so adjusted, present meaningful indicators of the Company’s actual sources and uses of capital associated with its operations conducted during the applicable period. Our computations of free cash flow and adjusted free cash flow may not be comparable to other similarly titled measures of other companies. Free cash flow and adjusted free cash flow should not be considered as alternatives to, or more meaningful than, net cash provided by operating activities as determined in accordance with GAAP or as indicators of our operating performance or liquidity.

Free cash flow and adjusted free cash flow are not financial measures that are determined in accordance with GAAP. Accordingly, the following table presents a reconciliation of free cash flow and adjusted free cash flow to net cash provided by operating activities, which is the most directly comparable financial measure calculated and presented in accordance with GAAP:

 

Accrued Capital Expenditure(1)

 

Cash Capital Expenditure(2)

 

Three Months Ended March 31,

 

Three Months Ended March 31,

(in thousands, except per share data)

 

2023

 

 

 

2022

 

 

 

2023

 

 

 

2022

 

Net cash provided by operating activities

$

438,213

 

 

$

160,120

 

 

$

438,213

 

 

$

160,120

 

Changes in working capital:

 

 

 

 

 

 

 

Accounts receivable

 

1,503

 

 

 

53,824

 

 

 

1,503

 

 

 

53,824

 

Prepaid and other assets

 

1,016

 

 

 

415

 

 

 

1,016

 

 

 

415

 

Accounts payable and other liabilities

 

6,811

 

 

 

(10,825

)

 

 

6,811

 

 

 

(10,825

)

Operating cash flow before working capital changes

 

447,543

 

 

 

203,534

 

 

 

447,543

 

 

 

203,534

 

Less: total capital expenditures incurred/paid

 

(359,800

)

 

 

(114,700

)

 

 

(315,285

)

 

 

(81,156

)

Free cash flow

 

87,743

 

 

 

88,834

 

 

 

132,258

 

 

 

122,378

 

Merger and integration expense

 

13,299

 

 

 

 

 

 

13,299

 

 

 

 

Adjusted free cash flow

$

101,042

 

 

$

88,834

 

 

$

145,557

 

 

$

122,378

 

 

 

 

 

 

 

 

 

Adjusted basic weighted average shares outstanding

 

559,282

 

 

 

284,851

 

 

 

559,282

 

 

 

284,851

 

Adjusted free cash flow per adjusted basic share

$

0.18

 

 

$

0.31

 

 

$

0.26

 

 

$

0.43

 

_________________________________

(1)

Utilizes activity-based capital expenditures incurred during the period.

(2)

Utilizes cash capital expenditure payments during the period.

Adjusted Net Income

Adjusted net income is a supplemental non-GAAP financial measure that is used by management and external users of our consolidated financial statements, such as industry analysts, investors, lenders and rating agencies. We define adjusted net income as net income attributable to Class A Common Stock plus net income/loss attributable to noncontrolling interest adjusted for non-cash gains or losses on derivatives, merger and integration expense, impairment and abandonment expense, gain/loss from the sale of long-lived assets and the related income tax adjustments for these items. Adjusted net income is not a measure of net income as determined by GAAP.

Our management believes adjusted net income is useful as it allows them to more effectively evaluate our operating performance and compare the results of our operations from period to period and against our peers by excluding certain non-cash items that can vary significantly. Adjusted net income should not be considered as an alternative to, or more meaningful than, net income as determined in accordance with GAAP or as an indicator of our operating performance or liquidity. Our presentation of adjusted net income should not be construed as an inference that our results will be unaffected by unusual or nonrecurring items. Our computations of adjusted net income may not be comparable to other similarly titled measures of other companies.

Adjusted net income is not a financial measure that is determined in accordance with GAAP. Accordingly, the following table presents a reconciliation of adjusted net income to net income, which is the most directly comparable financial measure calculated and presented in accordance with GAAP:

 

Three Months Ended March 31,

(in thousands, except per share data)

 

2023

 

 

 

2022

 

Net income (loss) attributable to Class A Common Stock

$

102,120

 

 

$

15,802

 

Net income (loss) attributable to noncontrolling interest

 

117,681

 

 

 

 

Non-cash derivative (gain) loss

 

(14,777

)

 

 

86,645

 

Merger and integration expense

 

13,299

 

 

 

 

Impairment and abandonment expense

 

245

 

 

 

2,627

 

(Gain) loss on sale of long-lived assets

 

(66

)

 

 

(82

)

Adjusted net income excluding above items

 

218,502

 

 

 

104,992

 

Income tax expense of the above items(1)

 

(26,186

)

 

 

(20,068

)

Adjusted Net Income

$

192,316

 

 

$

84,924

 

 

 

 

 

Adjusted basic weighted average shares outstanding

 

559,282

 

 

 

284,851

 

Adjusted net income per adjusted basic share

$

0.34

 

 

$

0.30

 

_______________________

(1)

Income tax expense for adjustments made to adjusted net income is calculated using PR’s federal and state-apportioned statutory tax rate of 22.5%.

The following table summarizes the approximate volumes and average contract prices of the hedge contracts the Company had in place as of April 30, 2023. There were no additional contracts entered into through the date of this filing:

 

Period

 

Volume (Bbls)

 

Volume

(Bbls/d)

 

Wtd. Avg. Crude Price ($/Bbl)(1)

Crude oil swaps

April 2023 – June 2023

 

1,592,500

 

17,500

 

$87.64

 

July 2023 – September 2023

 

1,748,000

 

19,000

 

84.93

 

October 2023 – December 2023

 

1,748,000

 

19,000

 

83.04

 

January 2024 – March 2024

 

1,547,000

 

17,000

 

76.65

 

April 2024 – June 2024

 

1,547,000

 

17,000

 

75.83

 

July 2024 – September 2024

 

1,564,000

 

17,000

 

75.06

 

October 2024 – December 2024

 

1,564,000

 

17,000

 

74.40

 

January 2025 – March 2025

 

450,000

 

5,000

 

68.00

 

April 2025 – June 2025

 

455,000

 

5,000

 

68.00

 

July 2025 – September 2025

 

460,000

 

5,000

 

68.00

 

October 2025 – December 2025

 

460,000

 

5,000

 

68.00

 

Period

 

Volume (Bbls)

 

Volume

(Bbls/d)

 

Wtd. Avg. Collar Price Ranges ($/Bbl)(2)

Crude oil collars

April 2023 – June 2023

 

819,000

 

9,000

 

$75.56 – $91.15

 

July 2023 – September 2023

 

644,000

 

7,000

 

76.43 – 92.70

 

October 2023 – December 2023

 

644,000

 

7,000

 

76.43 – 92.70

 

 

 

 

 

 

 

 

 

Period

 

Volume (Bbls)

 

Volume

(Bbls/d)

 

Wtd. Avg. Differential ($/Bbl)(3)

Crude oil basis differential swaps

April 2023 – June 2023

 

739,499

 

8,126

 

$0.55

 

July 2023 – September 2023

 

1,025,000

 

11,141

 

0.63

 

October 2023 – December 2023

 

1,025,002

 

11,141

 

0.63

 

January 2024 – March 2024

 

1,092,000

 

12,000

 

0.66

 

April 2024 – June 2024

 

1,092,000

 

12,000

 

0.66

 

July 2024 – September 2024

 

1,104,000

 

12,000

 

0.66

 

October 2024 – December 2024

 

1,104,000

 

12,000

 

0.66

 

January 2025 – March 2025

 

450,000

 

5,000

 

0.95

 

April 2025 – June 2025

 

455,000

 

5,000

 

0.95

 

July 2025 – September 2025

 

460,000

 

5,000

 

0.95

 

October 2025 – December 2025

 

460,000

 

5,000

 

0.95

 

Period

 

Volume (Bbls)

 

Volume

(Bbls/d)

 

Wtd. Avg. Differential

($/Bbl)(4)

Crude oil roll differential swaps

April 2023 – June 2023

 

1,365,000

 

15,000

 

$1.25

 

July 2023 – September 2023

 

1,656,000

 

18,000

 

1.16

 

October 2023 – December 2023

 

1,656,000

 

18,000

 

1.16

 

January 2024 – March 2024

 

1,092,000

 

12,000

 

0.68

 

April 2024 – June 2024

 

1,092,000

 

12,000

 

0.67

 

July 2024 – September 2024

 

1,104,000

 

12,000

 

0.66

 

October 2024 – December 2024

 

1,104,000

 

12,000

 

0.66

 

January 2025 – March 2025

 

180,000

 

2,000

 

0.37

 

April 2025 – June 2025

 

182,000

 

2,000

 

0.37

 

July 2025 – September 2025

 

184,000

 

2,000

 

0.37

 

October 2025 – December 2025

 

184,000

 

2,000

 

0.37

_______________________

(1)

These crude oil swap transactions are settled based on the NYMEX WTI index price on each trading day within the specified monthly settlement period versus the contractual swap price for the volumes stipulated.

(2)

These crude oil collars are settled based on the NYMEX WTI index price on each trading day within the specified monthly settlement period versus the contractual floor and ceiling prices for the volumes stipulated.

(3)

These crude oil basis swap transactions are settled based on the difference between the arithmetic average of ARGUS MIDLAND WTI and ARGUS WTI CUSHING indices, during each applicable monthly settlement period.

(4)

These crude oil roll swap transactions are settled based on the difference between the arithmetic average of NYMEX WTI calendar month prices and the physical crude oil delivery month price.

 

Period

 

Volume (MMBtu)

 

Volume (MMBtu/d)

 

Wtd. Avg. Gas Price

($/MMBtu)(1)

Natural gas swaps

April 2023 – June 2023

 

1,572,752

 

17,283

 

$4.70

 

July 2023 – September 2023

 

1,486,925

 

16,162

 

4.70

 

October 2023 – December 2023

 

1,413,628

 

15,366

 

4.90

 

January 2024 – March 2024

 

464,919

 

5,109

 

5.01

 

April 2024 – June 2024

 

446,321

 

4,905

 

3.93

 

July 2024 – September 2024

 

429,388

 

4,667

 

4.01

 

October 2024 – December 2024

 

413,899

 

4,499

 

4.32

 

 

 

 

 

 

 

 

 

Period

 

Volume (MMBtu)

 

Volume (MMBtu/d)

 

Wtd. Avg. Differential

($/MMBtu)(2)

Natural gas basis differential swaps

April 2023 – June 2023

 

6,142,500

 

67,500

 

$(1.30)

 

July 2023 – September 2023

 

6,210,000

 

67,500

 

(1.30)

 

October 2023 – December 2023

 

6,210,000

 

67,500

 

(1.30)

 

January 2024 – March 2024

 

1,820,000

 

20,000

 

(0.59)

 

April 2024 – June 2024

 

1,820,000

 

20,000

 

(0.67)

 

July 2024 – September 2024

 

1,840,000

 

20,000

 

(0.66)

 

October 2024 – December 2024

 

1,840,000

 

20,000

 

(0.64)

 

Period

 

Volume (MMBtu)

 

Volume (MMBtu/d)

 

Wtd. Avg. Differential

($/MMBtu)(3)

Natural gas basis differential swaps

April 2023 – June 2023

 

1,220,000

 

13,407

 

$(0.30)

 

July 2023 – September 2023

 

1,840,000

 

20,000

 

(0.30)

 

October 2023 – December 2023

 

1,840,000

 

20,000

 

(0.30)

 

January 2024 – March 2024

 

1,820,000

 

20,000

 

(0.06)

 

Period

 

Volume (MMBtu)

 

Volume (MMBtu/d)

 

Wtd. Avg. Collar Price Ranges

($/MMBtu)(4)

Natural gas collars

April 2023 – June 2023

 

6,389,748

 

70,217

 

$3.64 – $7.62

 

July 2023 – September 2023

 

6,563,075

 

71,338

 

3.64 – 7.52

 

October 2023 – December 2023

 

6,636,372

 

72,134

 

3.66 – 8.22

 

January 2024 – March 2024

 

3,175,081

 

34,891

 

3.36 – 9.44

 

April 2024 – June 2024

 

1,373,679

 

15,095

 

3.00 – 6.45

 

July 2024 – September 2024

 

1,410,612

 

15,333

 

3.00 – 6.52

 

October 2024 – December 2024

 

1,426,101

 

15,501

 

3.25 – 7.30

_____________________

(1)

These natural gas swap contracts are settled based on the NYMEX Henry Hub price on each trading day within the specified monthly settlement period versus the contractual swap price for the volumes stipulated.

(2)

These natural gas basis swap contracts are settled based on the difference between the Inside FERC’s West Texas WAHA price and the NYMEX price of natural gas, during each applicable monthly settlement period.

(3)

These natural gas basis swap contracts are settled based on the difference between the Houston Shipping Channel (“HSC”) price and the NYMEX price of natural gas, during each applicable monthly settlement period.

(4)

These natural gas collars are settled based on the NYMEX Henry Hub price on each trading day within the specified monthly settlement period versus the contractual floor and ceiling prices for the volumes stipulated.

 

Hays Mabry

Sr. Director, Investor Relations

(832) 240-3265

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Energy Other Energy Oil/Gas

MEDIA:

Logo
Logo

Guardant Health Announces Additions to Leadership Team

Guardant Health Announces Additions to Leadership Team

  • Ines Dahne-Steuber named as chief operating officer

  • Darya Chudova promoted to chief technology officer

 

PALO ALTO, Calif.–(BUSINESS WIRE)–
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief operating officer and the promotion of Darya Chudova to chief technology officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005605/en/

Ines Dahne-Steuber, Chief Operating Officer (Photo: Busines Wire)

Ines Dahne-Steuber, Chief Operating Officer (Photo: Busines Wire)

“At Guardant, we have built one of the most transformative platforms in diagnostics and we think extensively about how we get work done more efficiently, from development through delivery, to fulfill our primary mission of helping patients,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “As we scale our global operations, with an eye toward future product launches, Ines and Darya are uniquely qualified to help us succeed in this next exciting chapter of our journey.”

Ines Dahne-Steuber brings over 20 years of leadership and strategic expertise in healthcare operations. Prior to joining Guardant Health, she served as senior vice president of operational excellence and president of Spectra Laboratories at Fresenius Medical Care North America. Spectra Laboratories performs 100 million clinical and environmental tests serving over 200,000 dialysis patients per year. Prior to Fresenius Medical Care, she served in various leadership roles at Quest Diagnostics, most recently as general manager for oncology and vice president of healthcare IT solutions. Ms. Dahne-Steuber earned her Bachelor of Arts and Master’s degrees at Humboldt University in Berlin, Germany.

Darya Chudova has been with Guardant Health for eight years, most recently serving as the senior vice president of technology. In this role, she initially focused on leading technical development of Guardant360 LDT and CDx products improving the precision, robustness and accessibility of Guardant’s liquid biopsy tests. Most recently, she has led the development of Guardant’s ShieldTM technology for blood-based colorectal cancer screening, which is currently under review with the U.S. Food and Drug Administration. Prior to Guardant, Darya successfully developed tools for clinical diagnostics and interpretation of genomic expression and sequencing data in the context of molecular cytology at Veracyte, Inc. and non-invasive prenatal testing at Illumina, Inc. Ms. Chudova holds a Doctor of Philosophy degree from UC Irvine.

“We are very pleased to welcome Ines to Guardant’s leadership team. She brings a wealth of knowledge and operational expertise of lab operations,” said AmirAli Talasaz, co-CEO. “Darya has already been instrumental in our technology development over the last eight years. With the newly created role of chief technology officer, we are combining our research and development efforts across oncology and screening, and leveraging our single platform across multiple products to allow us to scale more efficiently. The leadership of both Ines and Darya will be extremely valuable as we continue to further improve our ability to operate effectively while balancing our need to innovate at pace.”

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Source: Guardant Health, Inc.

Investor Contact:

Alex Kleban

[email protected]

+1 657-254-5417

Media Contact:

Michael Weist

[email protected]

+1 317-371-0035

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Medical Devices Biometrics Health Technology General Health Biotechnology

MEDIA:

Photo
Photo
Ines Dahne-Steuber, Chief Operating Officer (Photo: Busines Wire)
Photo
Photo
Darya Chudova, Chief Technology Officer (Photo: Busines Wire)

TEN Ltd. Declares Dividend on its Series D and Series E Cumulative Perpetual Preferred Shares

ATHENS, Greece, May 08, 2023 (GLOBE NEWSWIRE) — TEN Ltd. (“TEN”) (NYSE: TNP) (the “Company”), a leading diversified crude, product and LNG tanker operator, today announced that its Board of Directors declared the regular quarterly cash dividend of $0.546875 per share for its Series D Cumulative Perpetual Preferred Shares (the “Series D Preferred Shares”; NYSE; TNPPRD) and the regular quarterly cash dividend of $0.578125 per share for its Series E Cumulative Perpetual Preferred Shares (the “Series E Preferred Shares”; NYSE; TNPPRE).

The dividend on the Series D and Series E is for the period from the most recent dividend payment date of February 28, 2023 through May 27, 2023.

The dividend on the Series D and E Preferred Shares will be paid on May 30, 2023 to all holders of record of Series D and E Preferred Shares as of May 24, 2023. Dividends on the Series D and E Preferred Shares are payable quarterly in arrears on the 28th day (unless the 28th falls on a weekend or public holiday, in which case the payment date is moved to the next business day) of February, May, August and November of each year, when, as and if declared by TEN’s board of directors. This is the 32nd dividend on the Series D and the 25th dividend on the Series E since their commencement of trading on the New York Stock Exchange.

TEN has 3,517,061 Series D and 4,745,947 Series E Preferred Shares outstanding as of the date of this press release.

ABOUT TSAKOS ENERGY NAVIGATION

TEN, founded in 1993 and celebrating this year 30 years as a public company, is one of the first and most established public shipping companies in the world. TEN’s diversified energy fleet currently consists of 67 double-hull vessels including four dual-fuel LNG powered Aframaxes, two scrubber-fitted Suezmaxes and up to three DP2 Shuttle tankers under construction constituting a mix of crude tankers, product tankers and LNG carriers, totaling 8.5 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Company

Tsakos Energy Navigation Ltd.
George Saroglou
COO
+30210 94 07 710
[email protected]

Investor Relations / Media

Capital Link, Inc.
Nicolas Bornozis
Markella Kara
+212 661 7566
[email protected]



Palantir Reports Its Second Consecutive Quarter of Positive GAAP Net Income; GAAP EPS of $0.01 in Q1 2023

Palantir Reports Its Second Consecutive Quarter of Positive GAAP Net Income; GAAP EPS of $0.01 in Q1 2023

DENVER–(BUSINESS WIRE)–
Palantir Technologies Inc. (NYSE:PLTR) today announced financial results for the first quarter ended March 31, 2023.

“We were profitable again this quarter… And we now anticipate that we will remain profitable each quarter through the end of the year,” Alexander C. Karp, co-founder and chief executive officer of Palantir Technologies Inc., wrote in a letter to shareholders. “The depth of engagement with and demand for our new Artificial Intelligence Platform (AIP) is without precedent.”

Q1 2023 Highlights

  • GAAP net income of $17 million

    • This marks our second consecutive quarter of positive GAAP net income

  • GAAP income from operations of $4 million, representing a margin of 1%, up 1,000 basis points year-over-year

    • This marks our first quarter of positive GAAP operating income

  • GAAP earnings per share (“EPS”) of $0.01

  • Adjusted EPS of $0.05

  • Total revenue grew 18% year-over-year to $525 million

    • US revenue grew 23% year-over-year to $337 million

  • Commercial revenue grew 15% year-over-year to $236 million

    • US commercial revenue grew 26% year-over-year to $107 million

  • Government revenue grew 20% year-over-year to $289 million

    • US government revenue grew 22% year-over-year to $230 million

  • Customer count grew 41% year-over-year and 7% quarter-over-quarter

    • US commercial customer count increased 50% year-over-year, from 103 customers in Q1 2022 to 155 customers in Q1 2023

  • Adjusted income from operations of $125 million, representing a margin of 24%

  • Cash from operations of $187 million, representing a 36% margin

  • Adjusted free cash flow of $189 million, representing a 36% margin

  • Cash, cash equivalents, and short-term U.S. treasury securities of $2.9 billion

Q1 2023 Financial Summary

 

(Amounts in thousands, except percentages and per share amounts)

First Quarter

Amount

Revenue

 

 

$

525,186

 

Year-over-year growth

 

 

 

18

%

 

 

 

 

 

Amount

 

Margin

Income from Operations

$

4,115

 

 

1

%

Adjusted Income from Operations

$

125,114

 

 

24

%

Cash from Operations

$

187,376

 

 

36

%

Adjusted Free Cash Flow

$

188,897

 

 

36

%

Net Income Attributable to Common Stockholders

$

16,802

 

 

Adjusted Net Income Attributable to Common Stockholders

$

107,401

 

 

Adjusted EBITDA

$

133,434

 

 

25

%

GAAP EPS, Diluted

$

0.01

 

 

Adjusted EPS, Diluted

$

0.05

 

 

Outlook

For Q2 2023, we expect:

  • Revenue of between $528 – $532 million.

  • Adjusted income from operations of $118 – $122 million.

  • GAAP net income.

For full year 2023, we expect:

  • Revenue of between $2.185 – $2.235 billion.

  • Adjusted income from operations of $506 – $556 million.

  • GAAP net income in each quarter.

CEO Letter

Palantir CEO Alex Karp’s quarterly letter to shareholders is available through Palantir’s website at https://www.palantir.com/q1-2023-letter.

Earnings Webcast

A live public webcast will be held at 3:00 PM MT / 5:00 PM ET today to discuss the results for our first quarter ended March 31, 2023 and financial outlook. The webcast can be accessed by registering online at https://palantir.events/palantir-earnings-q1-2023. A replay of the webcast will be available at https://investors.palantir.com following the event.

An investor presentation, including supplemental financial information and reconciliations of certain non-GAAP measures to their nearest comparable GAAP measures, will be available through Palantir’s Investor Relations website at https://investors.palantir.com.

Forward-Looking Statements

This press release and statements on our earnings webcast contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our financial outlook, product development and related timing, distribution, and pricing, expected benefits of and applications for our software platforms, business strategy, and plans (including strategy and plans relating to our Artificial Intelligence Platform (“AIP”), sales and marketing efforts, sales force, partnerships, and customers), investments in our business, market trends and market size, opportunities (including growth opportunities), our expectations regarding our existing and potential investments in, and commercial contracts with, various entities, our expectations regarding macroeconomic events and foreign currency fluctuations, and positioning. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “guidance,” “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “plan,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to risks detailed in our filings with the Securities and Exchange Commission (the “SEC”), including in our annual report on Form 10-K for the fiscal year ended December 31, 2022 and other filings and reports that we may file from time to time with the SEC, including our quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2023. In particular, the following factors, among others, could cause our results to differ materially from those expressed or implied by such forward-looking statements: our ability to successfully execute our business and growth strategy; the sufficiency of our cash and cash equivalents to meet our liquidity needs; the demand for our platforms, product offerings, and services in general; our ability to increase our number of new customers and revenue generated from customers; our ability to realize some or all of the total contract value of customer contracts as revenue, including any contractual options available to customers or contractual periods that are subject to termination for convenience provisions; our long and unpredictable sales cycle; our ability to successfully execute our channel sales and other strategic initiatives with third parties; our ability to retain and expand our customer base; the fluctuation of our results of operations and our key business measures on a quarterly basis in future periods; the seasonality of our business; the implementation process for our platforms, which may be complex and lengthy; our ability to successfully develop and deploy new technologies to address the needs of our existing or prospective customers; our ability to make our platforms and product offerings easier to install, consume, and use; our ability to maintain and enhance our brand and reputation; our ability to maintain and enhance our culture as our business grows and as we pursue our business and financial goals; news or social media coverage about us, including but not limited to coverage that presents, or relies on, inaccurate, misleading, incomplete, or otherwise damaging information; the impact of recent or future global macroeconomic and geopolitical events, such as the ongoing Russia-Ukraine conflict, rising inflation and interest rates in the U.S. and in other countries, monetary policy changes, financial services sector instability, and foreign currency fluctuations, on the business and operations of our company or of our existing or prospective customers and partners; and any breach or access to customer or third-party data.

The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Past performance is not necessarily indicative of future results.

Additional Definitions

For the purpose of this press release and our earnings webcast, total contract value (“TCV”) closed, remaining performance obligations, and total remaining deal value reflect the values of contracts that have been entered into with, or awarded by, our government and commercial customers.

TCV closed includes existing contractual obligations and presumes the exercise of all contract options available to our customers and no termination of contracts; however, the majority of our contracts are subject to termination provisions, including for convenience, and there can be no guarantee that contracts are not terminated or that contract options will be exercised.

Remaining performance obligations represent non-cancelable contracted revenue that has not yet been recognized, which includes deferred revenue and, in certain instances, amounts that will be invoiced. We have elected the practical expedient, as permitted under Accounting Standards Codification 606—Revenue from Contracts with Customers—allowing us to not disclose remaining performance obligations for contracts with original terms of twelve months or less.

Total remaining deal value is the total remaining value of contracts and includes existing contractual obligations and unexercised contract options available to those customers. Total remaining deal value presumes the exercise of all contract options and no termination of contracts; however, the majority of our contracts are subject to termination provisions, including for convenience, and there can be no guarantee that contracts are not terminated or that contract options will be exercised. Total remaining deal value excludes all or some portion of the value of certain commercial contracts as a result of our ongoing assessments of customers’ financial condition, including the consideration of such customers’ ability and intention to pay, and whether such contracts continue to meet the criteria for revenue recognition, among other factors.

Non-GAAP Financial Measures

This press release and the accompanying tables contain the non-GAAP financial measures adjusted income from operations, which excludes stock-based compensation and related employer payroll taxes; adjusted operating margin; adjusted free cash flow; adjusted free cash flow margin; adjusted earnings before interest, taxes, depreciation, and amortization (“adjusted EBITDA”); adjusted EBITDA margin; adjusted net income; and adjusted EPS, diluted.

We believe these non-GAAP financial measures and other metrics described in this press release help us evaluate our business, identify trends affecting Palantir’s business, formulate business plans and financial projections, and make strategic decisions. We exclude stock-based compensation, which is a non-cash expense, from these non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance and provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team. We exclude employer payroll taxes related to stock-based compensation as it is difficult to predict and outside of Palantir’s control.

Our definitions may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies may not publish these or similar metrics. Further, these metrics have certain limitations as they do not include the impact of certain expenses that are reflected in our consolidated statements of operations. For example, adjusted free cash flow does not reflect our future contractual commitments or the total increase or decrease in our cash balances for a given period. Thus, our non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to the most comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure.

A reconciliation table of the most comparable GAAP financial measure to each non-GAAP financial measure used in this press release is included at the end of this release. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, reconciling items that may be incurred in the future, such as stock-based compensation and related employer payroll taxes, the effect of which may be significant.

Available Information

Palantir uses its Investor Relations website at https://investors.palantir.com as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Palantir’s Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, and webcasts.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

 

Palantir Technologies Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Revenue

$

525,186

 

 

$

446,357

 

Cost of revenue (1)

 

107,645

 

 

 

94,403

 

Gross profit

 

417,541

 

 

 

351,954

 

Operating expenses:

 

 

 

Sales and marketing (1)

 

187,093

 

 

 

160,485

 

Research and development (1)

 

90,100

 

 

 

88,601

 

General and administrative (1)

 

136,233

 

 

 

142,307

 

Total operating expenses

 

413,426

 

 

 

391,393

 

Income (loss) from operations

 

4,115

 

 

 

(39,439

)

Interest income

 

20,853

 

 

 

547

 

Interest expense

 

(1,275

)

 

 

(594

)

Other income (expense), net

 

(2,861

)

 

 

(59,870

)

Income (loss) before provision for income taxes

 

20,832

 

 

 

(99,356

)

Provision for income taxes

 

1,681

 

 

 

2,023

 

Net income (loss)

 

19,151

 

 

 

(101,379

)

Less: Net income attributable to noncontrolling interests

 

2,349

 

 

 

 

Net income (loss) attributable to common stockholders

$

16,802

 

 

$

(101,379

)

Net earnings (loss) per share attributable to common stockholders, basic

$

0.01

 

 

$

(0.05

)

Net earnings (loss) per share attributable to common stockholders, diluted

$

0.01

 

 

$

(0.05

)

Weighted-average shares of common stock outstanding used in computing net earnings (loss) per share attributable to common stockholders, basic

 

2,107,780

 

 

 

2,036,307

 

Weighted-average shares of common stock outstanding used in computing net earnings (loss) per share attributable to common stockholders, diluted

 

2,217,439

 

 

 

2,036,307

 

________

(1) Includes stock-based compensation expense as follows (in thousands):

 

 

Three Months Ended March 31,

 

 

2023

 

 

2022

Cost of revenue

$

9,177

 

$

11,677

Sales and marketing

 

39,535

 

 

49,272

Research and development

 

19,924

 

 

26,905

General and administrative

 

46,078

 

 

61,469

Total stock-based compensation

$

114,714

 

$

149,323

 

Palantir Technologies Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

As of March 31,

 

As of December 31,

 

 

2023

 

 

 

2022

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

1,264,738

 

 

$

2,598,540

 

Marketable securities

 

1,639,797

 

 

 

35,135

 

Accounts receivable, net

 

254,041

 

 

 

258,346

 

Restricted cash

 

11,946

 

 

 

16,244

 

Prepaid expenses and other current assets

 

85,625

 

 

 

133,312

 

Total current assets

 

3,256,147

 

 

 

3,041,577

 

Property and equipment, net

 

63,115

 

 

 

69,170

 

Restricted cash, noncurrent

 

12,095

 

 

 

12,551

 

Operating lease right-of-use assets

 

210,019

 

 

 

200,240

 

Other assets

 

141,762

 

 

 

137,701

 

Total assets

$

3,683,138

 

 

$

3,461,239

 

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

4,530

 

 

$

44,788

 

Accrued liabilities

 

174,525

 

 

 

172,715

 

Deferred revenue

 

229,551

 

 

 

183,350

 

Customer deposits

 

139,741

 

 

 

141,989

 

Operating lease liabilities

 

53,066

 

 

 

45,099

 

Total current liabilities

 

601,413

 

 

 

587,941

 

Deferred revenue, noncurrent

 

54,400

 

 

 

9,965

 

Customer deposits, noncurrent

 

4,162

 

 

 

3,936

 

Operating lease liabilities, noncurrent

 

206,422

 

 

 

204,305

 

Other noncurrent liabilities

 

13,548

 

 

 

12,655

 

Total liabilities

 

879,945

 

 

 

818,802

 

Stockholders’ equity:

 

 

 

Common stock

 

2,117

 

 

 

2,099

 

Additional paid-in capital

 

8,568,570

 

 

 

8,427,998

 

Accumulated other comprehensive loss, net

 

(4,318

)

 

 

(5,333

)

Accumulated deficit

 

(5,842,636

)

 

 

(5,859,438

)

Total stockholders’ equity

 

2,723,733

 

 

 

2,565,326

 

Noncontrolling interests

 

79,460

 

 

 

77,111

 

Total equity

 

2,803,193

 

 

 

2,642,437

 

Total liabilities and equity

$

3,683,138

 

 

$

3,461,239

 

 

Palantir Technologies Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Operating activities

 

 

 

Net income (loss)

$

19,151

 

 

$

(101,379

)

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

8,320

 

 

 

4,312

 

Stock-based compensation

 

114,714

 

 

 

149,323

 

Noncash operating lease expense

 

10,836

 

 

 

10,142

 

Unrealized and realized (gain) loss from marketable securities, net

 

8,508

 

 

 

62,843

 

Other operating activities

 

(11,342

)

 

 

(2,754

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

(628

)

 

 

(65,867

)

Prepaid expenses and other current assets

 

1,973

 

 

 

(4,320

)

Other assets

 

(4,551

)

 

 

2,891

 

Accounts payable

 

(39,921

)

 

 

(47,404

)

Accrued liabilities

 

4,271

 

 

 

(5,334

)

Deferred revenue, current and noncurrent

 

88,673

 

 

 

(16,335

)

Customer deposits, current and noncurrent

 

(2,112

)

 

 

59,822

 

Operating lease liabilities, current and noncurrent

 

(10,536

)

 

 

(10,388

)

Other noncurrent liabilities

 

20

 

 

 

(75

)

Net cash provided by operating activities

 

187,376

 

 

 

35,477

 

Investing activities

 

 

 

Purchases of property and equipment

 

(4,755

)

 

 

(15,215

)

Purchases of marketable securities

 

(2,310,367

)

 

 

(89,500

)

Proceeds from sales and redemption of marketable securities

 

709,459

 

 

 

8,247

 

Proceeds from sales of alternative investments

 

51,072

 

 

 

 

Net cash used in investing activities

 

(1,554,591

)

 

 

(96,468

)

Financing activities

 

 

 

Proceeds from the exercise of common stock options

 

25,924

 

 

 

27,225

 

Other financing activities

 

59

 

 

 

16

 

Net cash provided by financing activities

 

25,983

 

 

 

27,241

 

Effect of foreign exchange on cash, cash equivalents, and restricted cash

 

2,676

 

 

 

(727

)

Net decrease in cash, cash equivalents, and restricted cash

 

(1,338,556

)

 

 

(34,477

)

Cash, cash equivalents, and restricted cash – beginning of period

 

2,627,335

 

 

 

2,366,914

 

Cash, cash equivalents, and restricted cash – end of period

$

1,288,779

 

 

$

2,332,437

 

 

Palantir Technologies Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(unaudited)

 

Non-GAAP Reconciliations

 

Adjusted Income from Operations and Adjusted Operating Margin (in thousands, except percentages)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Income (loss) from operations

$

4,115

 

 

$

(39,439

)

Add: stock-based compensation

 

114,714

 

 

 

149,323

 

Add: employer payroll taxes related to stock-based compensation

 

6,285

 

 

 

7,506

 

Adjusted income from operations

$

125,114

 

 

$

117,390

 

Adjusted operating margin

 

24

%

 

 

26

%

Adjusted Free Cash Flow and Adjusted Free Cash Flow Margin (in thousands, except percentages)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Net cash provided by operating activities

$

187,376

 

 

$

35,477

 

Add: cash paid for employer payroll taxes related to stock-based compensation

 

6,276

 

 

 

9,524

 

Less: purchases of property and equipment

 

(4,755

)

 

 

(15,215

)

Adjusted free cash flow

$

188,897

 

 

$

29,786

 

Adjusted free cash flow margin

 

36

%

 

 

7

%

Adjusted EBITDA and Adjusted EBITDA Margin (in thousands, except percentages)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Net income (loss) attributable to common stockholders

$

16,802

 

 

$

(101,379

)

Add: net income attributable to noncontrolling interests

 

2,349

 

 

 

 

Less: interest income

 

(20,853

)

 

 

(547

)

Add: interest expense

 

1,275

 

 

 

594

 

Add: other (income) expense, net

 

2,861

 

 

 

59,870

 

Add: provision for income taxes

 

1,681

 

 

 

2,023

 

Add: depreciation and amortization

 

8,320

 

 

 

4,312

 

Add: stock-based compensation

 

114,714

 

 

 

149,323

 

Add: employer payroll taxes related to stock-based compensation

 

6,285

 

 

 

7,506

 

Adjusted EBITDA

$

133,434

 

 

$

121,702

 

Adjusted EBITDA margin

 

25

%

 

 

27

%

Adjusted Net Income Attributable to Common Stockholders and Adjusted Earnings Per Share, Diluted (in thousands, except per share amounts)

 

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Net income (loss) attributable to common stockholders

$

16,802

 

 

$

(101,379

)

Add: stock-based compensation

 

114,714

 

 

 

149,323

 

Add: employer payroll taxes related to stock-based compensation

 

6,285

 

 

 

7,506

 

Less: income tax effects and adjustments (1)

 

(30,400

)

 

 

(10,737

)

Adjusted net income attributable to common stockholders

$

107,401

 

 

$

44,713

 

Weighted-average shares used in computing GAAP earnings (loss) per share, diluted

 

2,217,439

 

 

 

2,036,307

 

Adjusted weighted-average shares used in computing adjusted earnings per share, diluted (2)

 

2,217,439

 

 

 

2,209,310

 

Adjusted earnings per share, diluted

$

0.05

 

 

$

0.02

 

________

(1)

Income tax effect is based on long-term estimated annual effective tax rates of 23.0% and 22.2% for the periods ended 2023 and 2022, respectively.
 

(2)

Includes an additional 173 million dilutive securities for the three months ended March 31, 2022 that are excluded from a GAAP perspective due to the Company’s net loss position.

 

Investor Relations

[email protected]

Media

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Software Technology Artificial Intelligence

MEDIA:

Logo
Logo

Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint

Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient dosed 2Q23; initial results expected in 4Q23

Conference call at 4:30 pm ET today

BOSTON, May 08, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

“Highlights of the first quarter of 2023 include advancement of our clinical trials and R&D efforts, together with multiple data presentations at several scientific meetings in support of bemnifosbuvir’s favorable safety and drug interaction profile and its potential to address the key limitations of current therapies faced by patients with COVID-19 and HCV,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “The continued execution of the global geographical footprint of our Phase 3 SUNRISE-3 trial for COVID-19 and the recent U.S. Food and Drug Administration Fast Track designation granted to bemnifosbuvir, bring us closer to our goal of delivering an effective treatment to the millions of COVID-19 patients for whom the current standard of care is not a suitable option.”

“The initiation of our Phase 2 combination study of bemnifosbuvir and ruzasvir is an important milestone, and we look forward to initial results from our lead-in cohort of approximately 60 patients by year-end,” continued Dr. Sommadossi. “Nearly 300,000 people continue to die every year from HCV-related liver diseases, according to the World Health Organization. Our goal, supported by in vitro and clinical data generated to-date, is to significantly improve upon the current standard of care by offering a short duration, pan-genotypic, protease inhibitor-free treatment for patients with HCV, with or without cirrhosis.”


Bemnifosbuvir for COVID-19 Update

Granted Fast Track Designation by U.S. FDA: In April, Atea announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to bemnifosbuvir for the treatment of COVID-19. The FDA’s Fast Track program is designed to facilitate the expedited development and review of new drugs or biologics that are intended to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. Among other things, as a result of the Fast Track designation, Atea may benefit from more frequent communications with the FDA to discuss the development plan of bemnifosbuvir for the treatment of COVID-19 and rolling review of any completed sections of any resulting New Drug Application.

Bemnifosbuvir SUNRISE-3 trial in High-Risk Outpatients with COVID-19: Patient enrollment continues in the global, randomized, double-blind, placebo-controlled, registrational Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, a nucleotide polymerase inhibitor, administered concurrently with locally available standard of care. The study is designed to enroll at least 1,500 high-risk outpatients with mild or moderate COVID-19 at clinical trial sites worldwide, including in the U.S., Europe, and Japan. Patients are being randomized 1:1 to receive locally available standard of care and either bemnifosbuvir 550 mg twice-daily (BID) or placebo BID for five days. The primary endpoint of the study is all-cause hospitalization or death through Day 29 in the supportive care population comprised of at least 1,300 patients.

Presentation of Bemnifosbuvir Data Showing Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023): In April, Atea presented the full results from the MORNINGSKY trial, which evaluated bemnifosbuvir for the treatment of mild to moderate COVID-19. As previously announced, these results showed that non-hospitalized adult and adolescent patients who received bemnifosbuvir experienced a 71% relative reduction in risk of hospitalization, regardless of vaccination status (secondary endpoint). In an exploratory analysis, an 82% reduction in risk of hospitalization was seen in a subset of patients greater than 40 years of age. Based on these data, the global Phase 3 SUNRISE-3 registrational trial was initiated.

Favorable Drug Interaction Profile of Bemnifosbuvir Presented at 36
th
International Conference on Antiviral Research (ICAR 2023): In March, Atea presented Phase 1, in vitro and preclinical data that demonstrated key profile attributes of bemnifosbuvir. The data presented included results from a Phase 1 human absorption, distribution, metabolism, and excretion (ADME) study for bemnifosbuvir demonstrating a favorable ADME profile supportive of the dosing regimen being evaluated in SUNRISE-3. In vitro metabolism and transporter interaction studies showed bemnifosbuvir has a low risk for interactions with medicines commonly taken by COVID-19 high risk patients for other conditions. In vitro studies also demonstrated advantages of bemnifosbuvir’s mechanism of action, which targets conserved regions of the virus that causes COVID-19. These potential advantages include a high barrier to resistance and maintenance of antiviral activity in the presence of COVID-19 variants.

Favorable Profile of Bemnifosbuvir Related to Low Risk for Drug-Drug Interactions Presented at Conference on Retroviruses and Opportunistic Infections (CROI 2023)
: In February, Atea presented data from three Phase 1 studies that showed the favorable drug-drug interaction profile of bemnifosbuvir. The results of these studies, including a study with midazolam, indicate that no dosage adjustment of CYP3A substrates or of drugs that are sensitive substrates of efflux and hepatic uptake transporters is likely to be needed when co-administrated with bemnifosbuvir. CYP3A is an enzyme that metabolizes many classes of medicines and medicinal supplements, and efflux/hepatic uptake transporters regulate cellular trafficking of many medicines that are commonly prescribed to COVID-19 high risk patients.

Bemnifosbuvir Retains Antiviral Activity Against Omicron Subvariant XBB 

In Vitro

AT-511, the free base of bemnifosbuvir, has been shown to be a potent inhibitor of SARS-CoV-2 in vitro. New results demonstrated that AT-511 retained potent antiviral activity against the SARS-CoV-2 Omicron subvariant XBB. AT-511 has previously demonstrated in vitro potent antiviral activity against other variants of concern and/or of interest, including Alpha, Beta, Gamma, Epsilon, Delta and Omicron subvariants BA.1, BA.2, BA.4, and BA.5.

COVID-19 Program for Second Generation Protease Inhibitors: As part of a multipronged approach against COVID-19, Atea is engaged in efforts directed to the discovery of second-generation protease inhibitors that have clinical profiles well suited for combination with bemnifosbuvir for the treatment of COVID-19. These efforts are supported by in vitro studies which have demonstrated that the combination of bemnifosbuvir and nirmatrelvir have an additive antiviral effect and the expectation that certain patient populations will require combination therapy. Activities to select a novel proprietary compound are underway.


Hepatitis C Virus (HCV) Program Update

Phase 2 HCV Combination Study: Atea is on track to initiate patient dosing in the second quarter of 2023 in the Phase 2 combination study of bemnifosbuvir and ruzasvir, an oral NS5A inhibitor.

This open label Phase 2 study is expected to enroll approximately 280 HCV-infected, direct-acting antiviral naive patients across all genotypes, including a 60 patient lead-in cohort. Patients will be administered 550 mg bemnifosbuvir in combination with 180 mg ruzasvir once-daily for eight weeks. The primary endpoints of the study are safety and sustained virologic response (SVR) at Week 12 post-treatment. Other virologic endpoints include virologic failure, SVR at Week 24 post-treatment and resistance. Initial data from the 60-patient lead-in cohort is anticipated in the fourth quarter of 2023.

Synergistic Antiviral Effect Observed for the Combination of Bemnifosbuvir + Ruzasvir Against HCV

In Vitro

Presented at
36th International Conference on Antiviral Research (ICAR 2023): In March, Atea presented in vitro data demonstrating that the combination of bemnifosbuvir and ruzasvir had greater inhibition of HCV replication than the sum of both compounds alone, suggesting a synergistic antiviral effect when bemnifosbuvir and ruzasvir were administered together.

In vivo results from a 13-week toxicity study in rats also demonstrated that systemic exposures of bemnifosbuvir, its metabolites, and ruzasvir were similar when administered independently or in combination, suggesting no significant drug-drug interactions between bemnifosbuvir and ruzasvir.

This synergistic activity and no significant drug-drug interactions, together with the previously demonstrated potent, pan-genotypic, antiviral activity of each agent alone, support the initiation of the Phase 2 combination of bemnifosbuvir and ruzasvir, which has the potential to offer a differentiated, short duration, pan-genotypic, protease inhibitor-sparing regimen for patients with HCV, with or without cirrhosis.

New

In Vitro

Bemnifosbuvir and Ruzasvir Data: New data from an in vitro study demonstrated that bemnifosbuvir is at least 10 times more potent than sofosbuvir and retains full potency against all HCV GT-1a and GT-3a NS5A resistance associated variants (RAVs) tested. In addition, new data show that ruzasvir is more potent than velpatasvir and retains a favorable potency profile against a panel of HCV GT-1a and GT-3a NS5A RAVs. Based on these in vitro data combined with other data to-date, it is expected that the combination of bemnifosbuvir and ruzasvir will retain antiviral activity against major clinically relevant HCV NS5A RAVs.


Dengue Program Update

Data presented at ECCMID 2023, and recently published in the peer-reviewed journal, Antiviral Research, together with data to-date, indicate a favorable biological, pharmacological and safety profile for AT-752. However, due to the anticipated long clinical timelines and major associated costs, Atea deprioritized its dengue program and the development of AT-752 in February 2023 and made the business decision to focus on its COVID-19 and HCV programs.


First Quarter 2023 Financial Results

Cash, Cash Equivalents and Marketable Securities: $620.5 million at March 31, 2023 compared to $646.7 million at December 31, 2022.

Research and Development Expenses: Research and development expenses remained relatively consistent at $29.0 million for the quarter ended March 31, 2023 compared to $29.6 million for the quarter ended March 31, 2022.

General and Administrative Expenses: General and administrative expenses remained relatively consistent at $12.6 million for the quarter ended March 31, 2023 compared to $12.5 million for the quarter ended March 31, 2022.

Interest Income and Other, Net: Interest income and other, net was $6.3 million for the quarter ended March 31, 2023 compared to $0.1 million for the quarter ended March 31, 2022. The increase was primarily the result of investing in higher yield marketable securities and higher interest rates.

Income Taxes: Income tax expense was $0.2 million for the quarter ended March 31, 2023. Atea did not record income tax expense for the quarter ended March 31, 2022.

Condensed Consolidated Statement of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
  Three Months Ended

March 31,
    2023     2022  
Operating expenses:            
Research and development         $ 28,954   $ 29,633  
General and administrative           12,615     12,542  
Total operating expenses           41,569     42,175  
Loss from operations           (41,569 )   (42,175 )
Interest income and other, net           6,299     98  
Loss before income taxes           (35,270 )   (42,077 )
Income tax expense           (197 )    
Net loss         $ (35,467 ) $ (42,077 )
Other comprehensive income:            
Unrealized gains on available-for-sale            377    
Comprehensive loss         $ (35,090 ) $ (42,077 )
Net loss per share – basic and diluted         $ (0.43 ) $ (0.51 )
Weighted-average common shares used in computing net loss per share – basic and diluted           83,332,397     83,176,408  

Selected Condensed Consolidated Balance Sheet Data
(in thousands)
  March 31, 2023


  December 31, 2022
  (unaudited)


   
Cash, cash equivalents, and marketable securities         $ 620,488   $ 646,709
Working capital(1)   620,029     642,444
Total assets   638,131     666,708
Total liabilities   19,949     26,136
Total stockholders’ equity   618,182     640,572

(1) Atea defines working capital as current assets less current liabilities. See the Company’s condensed consolidated financial statements in its Quarterly Report on Form 10-Q for the three months ended March 31, 2023 for further detail regarding its current assets and liabilities.

Conference Call and Webcast

Atea will host a conference call and live audio webcast to discuss first quarter 2023 financial results and provide a business update today at 4:30 p.m. ET. To access the live conference call, please register here. A live audio webcast of the call and accompanying slide presentation will also be available in the Investors’ Events & Presentations section of the Company’s website, www.ateapharma.com. To participate via telephone, please register in advance here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived copy of the audio webcast will be available on the Atea website approximately two hours after the event.

About Atea Pharmaceuticals

Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Currently, Atea is focused on the development of orally-available antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and hepatitis C virus (HCV). For more information, please visit www.ateapharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, including bemnifosbuvir for the treatment of COVID-19, any new protease inhibitor we may advance for clinical development in combination with bemnifosbuvir for the treatment of COVID-19 and the combination of bemnifosbuvir and ruzasvir for the treatment of HCV. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
[email protected]

Will O’Connor
Stern Investor Relations
212-362-1200
[email protected]